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ABSTRACT 
 
The diagnostic evaluation of ever smokers with pulmonary nodules represents a 
growing clinical challenge due to the implementation of lung cancer screening. The high 
false-positive rate of screening frequently results in the use of unnecessary invasive 
procedures in patients who are ultimately diagnosed as benign, clearly highlighting the 
need for additional diagnostic approaches. We previously derived and validated a 
bronchial epithelial gene-expression biomarker to detect lung cancer in ever smokers. 
However, bronchoscopy is not always chosen as a diagnostic modality. Given that 
bronchial and nasal epithelial gene-expression are similarly altered by cigarette smoke 
exposure, we sought to determine if cancer-associated gene-expression might also be 
detectable in the more readily accessible nasal epithelium. 
Nasal epithelial brushings were prospectively collected from ever smokers 
undergoing diagnostic evaluation for lung cancer in the AEGIS-1 (n=375) and AEGIS-2 
(n=130) clinical trials and gene-expression profiled using microarrays. The computational 
framework used to discover biomarkers in these data was formalized and implemented in 
an open-source R-package. 
We identified 535 genes in the nasal epithelium of AEGIS-1 patients whose 
	 vii 
expression was associated with lung cancer status. Using matched bronchial gene-
expression data from a subset of these patients, we found significantly concordant cancer-
associated gene-expression alterations between the two airway sites. A nasal lung cancer 
classifier derived in the AEGIS-1 cohort that combined clinical factors and nasal gene-
expression had significantly higher AUC (0.81) and sensitivity (0.91) than the clinical-
factor model alone in independent samples from the AEGIS-2 cohort. These results 
support that the airway epithelial field of lung cancer-associated injury extends to the 
nose and demonstrates the potential of using nasal gene-expression as a non-invasive 
biomarker for lung cancer detection. 
The framework for deriving this biomarker was generalized and implemented in an 
open-source R-package. The package provides a computational pipeline to compare 
biomarker development strategies using microarray data. The results from this pipeline 
can be used to highlight the optimal model development parameters for a given dataset 
leading to more robust and accurate models. This package provides the community with a 
novel and powerful tool to facilitate biomarker discovery in microarray data. 
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Chapter 1
GENERAL INTRODUCTION
1.1 Lung Cancer
Lung cancer is the leading cause of cancer-related death both in the United States and
world-wide. An estimated 158 thousand people in the United States will fall victim to the
disease in 2016 [94]. Lung cancer is the second most diagnosed form of cancer in both men
and women with 224 thousand combined annual diagnoses (14% of all cancer diagnoses);
second only to prostate cancer in men and breast cancer in women [94]. The high mortality
rate of lung cancer is due to the fact that the vast majority (79%) of tumors are diagnosed
at late stage, after the disease has progressed to the lymph nodes or metastasized. The five-
year survival rate of lung cancer as a whole is approximately 18%, however for later stage
disease, the survival rate drops dramatically from 28% for patients with regional disease
to 4.3% for patients with distant, metastatic tumors [46]. The high mortality rate of lung
cancer is due, in large part, to a lack of early detection when the disease is localized and
surgical resection is still a viable intervention. Given that patients do not typically present
with symptoms of lung cancer until their disease has progressed, there is a clear need to
identify accurate measures of risk that would allow for the prioritization and monitoring of
high-risk individuals.
1.2 Lung Cancer Screening
Lung cancer has historically been thought of as a smoker's disease which is supported by
the fact that roughly 80% of all patients who develop lung cancer have a history of cigarette
smoking [94]. However, cigarette smoking on its own is not a strong predictor of lung
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cancer as only approximately 10% of people who smoke will ultimately develop a lung
tumor. Many studies have been published showing the relationship between other clinical
covariates, such as age, gender, and smoking history, with a patient's risk of having or
developing lung cancer and many have put forth risk models and calculators to determine
pre-test risk [68, 99, 39, 69, 24]. These clinical covariates have been used to prioritize
screening and follow up of smokers who are at the highest risk of lung cancer.
In 2011, the National Lung Screening Trial demonstrated a feasible and effective strat-
egy for screening this high-risk population for lung cancer. The trial, which recruited over
53 thousand high-risk current and former smokers, examined the efficacy of administering
annual low-dose chest CT (LDCT) scans vs chest X-rays in the detection lung cancer. They
found that patients who underwent annual screening by LDCT had a 20% relative reduction
in lung cancer mortality compared to those who received chest X-ray [71]. The trial was
stopped early due to positive results and these findings have since spurred the development
of lung cancer screening programs nation-wide.
Of the 75 thousand screenings by LDCT that took place during the trial, 25% had
pulmonary nodules suspicious for lung cancer. Of these, >95% were ultimately diagnosed
as benign resulting in a false-positive rate of screening of >95%. While only 11% of
patients (n = 2033) with suspicious nodules were followed up with an invasive diagnostic
procedure, the high false positive rate of LDCT screening highlights the need for more
effective tools that can be used to assist physicians in the management of patients with
indeterminate pulmonary nodules.
1.3 Lung Cancer Diagnosis
To begin to craft a solution to the challenge of identifying lung cancer prior to, or on
the basis of, the results from chest imaging, it is critical to understand how patients enter
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and traverse the lung cancer diagnostic workflow. There are three primary avenues by
which a patient can enter the diagnostic workflow. First, as mentioned above, high-risk
ever smokers may undergo diagnostic evaluation given a pulmonary nodule suspicious for
lung cancer on LDCT. The second group includes patients who present with symptoms of
lung cancer, such as trouble breathing or coughing up blood. The third group, which has
been growing with the implementation and accessibility of lung cancer screening, consists
of patients with nodules identified incidentally on CT. This population, which totals 1.5
million patients annually in the U.S., typically enters the clinic for a matter unrelated to
lung cancer, however, after chest imagining, a suspicious nodule is identified and the patient
begins a diagnostic workup for lung cancer.
Follow up procedures for these patients are largely dependent upon each patient's pre-
test risk of lung cancer. Pre-test risk is calculated using one of a number of calculators and
typically incorporates clinical covariates such as age and gender, smoking history informa-
tion such as current or former smoking habits, characteristics of the nodule, concomitant
lung disease, and physician intuition. Management of patients at the extreme ends of the
pre-test risk spectrum is relatively straight forward. Patients with a pre-test risk <10% are
typically monitored non-invasively via repeat chest imaging while patients with pre-test
risk ≥60% tend to be followed up with more invasive procedures to diagnose or resect
the mass. Management of patients with intermediate pre-test risk (≥10, <60) is not clear
and physicians will typically resort to functional imaging or more invasive procedures to
inform the diagnosis. The availability of a non-invasive tool that could aid physicians in
the assessment of patients with intermediate pre-test risk would have tremendous clinical
utility.
3
1.4 Early Diagnostic Tools
A number of non-invasive biomarkers derived from sputum, blood, and airway epithelium
have been proposed in the literature but few have undergone the rigorous validation studies
required to substantiate their clinical utility. Many of these studies fall short in one or
more key study design attributes such as insufficient sample size or lack of an independent
validation set that is representative of the clinical setting in which the test would be applied.
One success story, though, is the development of a bronchial epithelial genomic classifier to
differentiate between patients with and without lung cancer. The biomarker utilizes patient
age and the expression profiles of 23 genes in bronchial epithelial cells obtained during
bronchoscopy to predict a patient’s cancer status and was prospectively validated in two
clinical trials and over 600 patients [95, 114, 90]. This biomarker was rationalized based
on the concept that an airway-wide field of injury exists in current and former smokers after
chronic exposure to tobacco smoke. Given that 80% of lung cancers occur in ever smokers,
it is not surprising, then, that a subset of the gene expression alterations in the field of injury
are associated with the development of a tumor. The procurement of bronchial epithelial
cells, however, limits the number of patients in which this test can be administered since
bronchoscopy is not always chosen as the diagnostic modality in patients with suspect lung
cancer. Chapter 2 details the natural extension of the airway field of injury concept from
bronchial to nasal epithelium and describes the development of a nasal biomarker for lung
cancer diagnosis.
1.5 Computational Challenges in Biomarker Development
Beyond the challenges associated with clinical utility and study design, the computational
development and validation of a candidate biomarker represents a complicated, multi-step
process that must be carefully implemented and traversed. One of the key computational
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challenges associated with biomarker development is the navigation of the design process.
A typical workflow includes quality control, data normalization, batch effect correction,
dimensionality reduction, feature selection, and classification. Within each of these steps,
there are a number of decisions that need to be made by the development team including
which method and parameters to use. Many studies have shown that teams with compu-
tational experience building biomarkers produce biomarkers that are more stable and have
higher performance in independent data than less experienced teams [89, 101]. These stud-
ies have also shown that there is no single method that performs well on all datasets and
that the selection and fine tuning of development parameters needs to be performed by the
analysis team to identify an optimal solution. We have previously developed a strategy for
building biomarkers from high dimensional genomic data that evaluates the performance
of hundreds or thousands of potential biomarker models in an unbiased manner. This sys-
tematic evaluation of models allows us to discover which methods work well together to
find the optimal biomarker development procedure for a given dataset. Chapter 3 describes
a formalization and extension of this methodology into an open-source R-package.
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Chapter 2
SHARED GENE EXPRESSION ALTERATIONS IN NASAL AND BRONCHIAL
EPITHELIUM FOR LUNG CANCER DETECTION
2.1 Introduction
The diagnostic evaluation of lung cancer among high-risk current and former smokers with
lesions found on chest imaging represents a growing clinical challenge due to the imple-
mentation of lung cancer screening [117]. While the National Lung Cancer Screening Trial
(NLST) demonstrated a 20% relative reduction in lung cancer-related mortality through
annual screening of high-risk smokers by low-dose chest CT (LDCT), approximately 25%
of CT-screened subjects had a pulmonary lesion, of which over 95% were ultimately diag-
nosed as benign [71]. While there are guidelines for the management of pulmonary nodules
[79], unnecessary invasive procedures (including surgical lung biopsy) are frequently per-
formed on patients who are ultimately diagnosed with benign disease [100, 118]. There is
a clear and growing need to develop additional diagnostic approaches for evaluating pul-
monary lesions to determine which patients should undergo CT surveillance or invasive
biopsy.
Our group and others have established that airway gene expression signatures can serve
as biomarkers for the presence of smoking-related lung diseases including lung cancer and
COPD [95, 97, 10]. Previous work has shown that chronic exposure to tobacco smoke
results in an airway-wide field of injury with both reversible and irreversible alterations
in bronchial airway epithelial cell gene expression upon smoking cessation [17, 7]. Im-
portantly, gene expression profiles from cytologically-normal bronchial epithelial cells ob-
tained via endobronchial brushings can serve as a biomarker that distinguishes ever smok-
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ers with lung cancer from those with benign lung disease [95] independently of clinical risk
factors [7]. More recently, Whitney et al. reported a 23-gene bronchial genomic lung can-
cer classifier [114], which was validated in two prospective clinical trials [90]. While the
high sensitivity and negative predictive value of this classifier suggest that it can be used to
assign patients to CT surveillance, it is dependent upon cells obtained during bronchoscopy.
Although bronchoscopy-related complications are uncommon [73, 107], bronchoscopy is
not always chosen as a diagnostic modality based on the size/location of the lung lesion,
pretest risk of disease, patient preference and degree of underlying lung disease.
Given concordant response of nasal and bronchial epithelium to tobacco smoke [122]
and the validated performance of the bronchial genomic classifier for lung cancer, we
sought to test the hypothesis that cancer-associated expression differences might also be
detectable in nasal epithelium and related to those found in bronchial epithelium. Detect-
ing cancer-associated gene expression in nasal epithelium would suggest its potential to
serve as a less invasive biospecimen for lung cancer detection and potentially expand the
clinical settings in which airway gene expression could be used for this purpose.
2.2 Methods
2.2.1 Experimental Design
Patients were enrolled at 28 medical centers in the US, Canada and Europe as part of
two prospective studies within the Airway Epithelial Gene Expression in the Diagnosis
of Lung Cancer (AEGIS) clinical trials (registered as NCT01309087 and NCT00746759).
All study protocols were approved by the institutional review board at each medical center
and written informed consent was obtained from all patients prior to enrollment. Inclusion
and exclusion criteria have been previously described [90]. All patients were current or
former cigarette smokers (>100 cigarettes in their lifetime) undergoing bronchoscopy as
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part of their diagnostic workup for clinical suspicion of lung cancer and all samples were
collected prospectively prior to diagnosis. Patients were followed for up to one year post-
bronchoscopy until a final diagnosis of lung cancer or benign disease was made. Given
that these clinical trials were enriched for patients that were ultimately diagnosed with
lung cancer, we were limited by the number of samples we could select that had a benign
diagnosis at 1 year follow up. From among the 1067 nasal samples collected in the AEGIS-
1 and AEGIS-2 clinical trials, we selected 554 samples for microarray profiling, matching
patients with benign diagnoses approximately 2:3 to patients diagnosed with lung cancer.
We selected all benign samples with sufficient RNA yield after isolation and then selected
cancer samples to best match the gender, age, pack-years, and smoking status of the benign
group. Microarray data generated from bronchial epithelium samples from 299 patients
together with their clinical annotations were obtained from Whitney et al. [114].
2.2.2 Nasal Epithelial Cell Collection & RNA Processing
Nasal epithelial cells were collected by brushing the lateral aspect of the inferior turbinate
with a single sterile cytology brush. Brushings were immediately placed into an RNA
preservative (Qiagen RNAProtect, Cat. 76526). Nasal epithelial cells were processed to
isolate RNA using Qiagen miRNeasy Mini Kits (Cat. 217004) per the manufacturer's pro-
tocol. RNA concentration and purity were assessed using a NanoDrop ND-1000 spec-
trophotometer (Thermo Scientific) and RNA integrity (RIN) was assessed using the 2100
Bioanalyzer (Agilent Technologies). RNA was subsequently stored at -80◦C until process-
ing on microarrays.
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2.2.3 Microarray Processing
All analytical methods were carried out using the R statistical computing environment. The
quality of each microarray CEL file was assessed using the ArrayQualityMetrics R pack-
age [50] which also provided recommended threshold values for identifying poor quality
samples. Nine metrics were computed per CEL file (6 prior to RMA normalization, and
3 post-RMA normalization and batch correction). Samples failing at least three quality
metrics were removed from all subsequent analyses.
All procedures were performed as previously described [97] using Affymetrix Gene 1.0
ST microarrays. CEL files from nasal and bronchial samples passing quality control were
processed separately using the Robust Multichip Average (RMA) algorithm [47] and the
standard Affymetrix Chip Definition File to estimate gene expression signal. ComBat [48]
was used to correct for microarray-processing batch effects. No covariates were included
in the ComBat model.
2.2.4 Low-Level Expression Filter
For differential expression analyses in nasal samples, only probesets that were expressed in
at least 5% of samples were included to reduce noise and data dimensionality. Background-
level expression was determined by examining the expression level of the Y-chromosome
genes DDX3Y, KDM5D, RPS4Y1, and USP9Y represented by probesets 8176375, 8176578,
8176624, 8177232 in female samples from the training set. Probesets whose expression
level did not exceed 1.5 positive standard deviations of the mean expression of the four
Y-linked genes in at least 5% of samples were not considered in the analyses.
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2.2.5 Characterization of Cancer Associated Genes in Nasal Epithelium
Cancer-associated gene expression profiles in nasal epithelium were identified using linear
models [92] that corrected for smoking status, pack years, gender, age, and RNA quality
(RIN). The most differentially expressed genes (p<0.001) were clustered using unsuper-
vised hierarchical clustering with Pearson distance and Ward linkage. The sample dendro-
gram was cut to yield two groups of samples. The difference in the proportion of cancer
samples to benign samples in each group was tested using a Pearson's Chi-squared test for
count data. Functional enrichment of the most differentially expressed genes (p < 0.001)
was assessed using the Reactome and Gene Ontology (GO) databases and EnrichR [20].
Similarities between cancer-associated gene expression profiles in nasal and bronchial ep-
ithelium were assessed using a pre-ranked Gene Set Enrichment Analysis (GSEA [98]).
Briefly, the most significantly differentially expressed genes in nasal epithelium were seg-
regated into up-regulated and down-regulated gene sets. Using the bronchial epithelium
gene expression data, each gene's association with cancer was assessed using a linear model
which yielded a moderated (empirical Bayes) t-statistic used to rank the genes in descend-
ing order. The pre-ranked function within the GSEA software package was then used to de-
termine whether either of the two nasal gene sets was enriched among the most up-regulated
or down-regulated genes in bronchial samples. Normalized enrichment scores and p-values
were calculated using the GSEA software tool [98]. The component of each significantly
enriched gene set that contributed most strongly to the enrichment (the “leading edge” or
“core enrichment”) was identified from the GSEA enrichment report. These genes were
clustered in nasal samples using unsupervised hierarchical clustering with Ward linkage.
Similar to the approach delineated above, the sample dendrogram for both the bronchial
and nasal samples was cut to yield two groups of samples and Pearson's Chi-squared test
for count data was used to test the difference in the proportion of cancer samples to benign
10
samples in each group.
The expression of eleven gene clusters previously identified as being associated with
cancer in the bronchial epithelium [114] was summarized in AEGIS-1 nasal samples by
taking the mean of the cluster genes per sample. The association of each cluster mean with
the presence or absence of cancer was computed using a Welch t-test. Finally, the corre-
lation of scores from a previously reported bronchial genomic lung cancer classifier [114]
was evaluated in matched bronchial and nasal samples from AEGIS-1 (n=157 patients). To
account for the potential difference in baseline gene expression levels between bronchial
and nasal tissues, we estimated a quantity to adjust the expression of each gene in the nasal
samples using nasal samples that had a matched bronchial sample in the training set in
which the bronchial classifier was developed (n=157) [114]. Specifically, the mean expres-
sion of each gene in nasal samples (n=157) was subtracted from its corresponding mean
expression in bronchial samples. The difference was then added to that gene's expression
level in each nasal sample. The bronchial genomic classifier score was then calculated on
the mean-shifted nasal data.
2.2.6 Derivation of Nasal Clinicogenomic Lung Cancer Classifier
We derived a clinical factor lung cancer classifier using a training set of AEGIS-1 patients
(n = 517) using logistic regression to combine patient age, smoking status (current, former),
time since quit ≤15 years, >15 years, unknown), and mass size (<3cm, ≥3cm, infiltrates).
The clinical data used to train this clinical factor model consisted of data from the 375
patients in our nasal training set, as well as 142 patients from the bronchial cohort that did
not have a matched nasal sample in the training set. Similarly, we derived a clinicogenomic
classifier using penalized logistic regression to combine all of the variables in the clinical
factor model plus the score from a nasal lung cancer gene expression described above in
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the subset of training samples with nasal gene expression data (n= 375). We were missing
mass size annotation on a small number of patients (5%; n = 18) in our training set and
these samples were excluded when training the models. For both the clinical classifier and
the clinicogenomic classifier, an elastic net logistic regression model with cancer status as
the dependent variable was derived using the penalized R package [37]. This model was
chosen because of its demonstrated utility in combining clinical and genomic variables in
a single, easily interpretable model [95]. Unpenalized independent variables in the model
included the smoking status, time since quit, patient age, and mass size. In the clinicoge-
nomic model, the cancer gene expression classifier score was included as the only penalized
independent variable in the model.
2.2.7 Cross-Validation and Optimization of the Lung Cancer Gene Expression Classi-
fier
The training set was randomly divided with 80% of samples assigned to an internal training
set and the remaining 20% of samples assigned to an internal test set. Within each internal
training set, the association of each gene's expression with cancer status was assessed using
Student's t-test. The genes were ranked by absolute t-statistic and a varying number of the
top-ranked genes were selected for inclusion in the classifier. Six classification algorithms
were evaluated including glmnet, Naïve Bayes, KNN, support vector machines, random
forest, and weighted voting. Weighted voting was chosen as the optimal classification
algorithm as it achieved the highest AUC in cross-validation. With the classification algo-
rithm selected, classifiers composed of 5 to 100 genes were evaluated. The performance of
each internally trained classifier was quantified using the AUC in the internal test set. This
cross-validation procedure was repeated for 100 iterations. The AUC values across the 100
splits of the data were used to rank the models. The optimal model was chosen after man-
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ual inspection of the cross-validation results with the goal of selecting a model with a high
average AUC, small standard deviation of AUC across all iterations, and a small number of
genes included in the classifier, relative to all other models. The genes included in the final
model were selected and the final weighted voting classifier was trained using the entire
training set and completely specified prior to evaluation in the validation set.
2.2.8 Statistical Analyses
Differences in clinical covariates between patients with and without lung cancer were as-
sessed using Fisher's exact test (categorical variables) or Welch t-test (continuous vari-
ables). Differential expression analyses were performed using linear modeling (limma R
package [92]) or Welch t-tests unless otherwise specified. Correlation coefficients were
calculated using Pearson's product-moment coefficient. Classification performance was as-
sessed using standard measures including receiver operating characteristic (ROC) curve,
the area under the curve (AUC), sensitivity, specificity, negative predictive value (NPV),
and positive predictive value (PPV). Differences between ROC curve AUC values were
assessed using DeLong's test [25] for correlated ROC curves. Operating points for binary
classification were chosen as the threshold that maximized sensitivity while maintaining
50% specificity in the training set. Differences in sensitivity and specificity between mod-
els were assessed using McNemar's chi-squared test for count data [3]. Statistical differ-
ences in NPV between models were assessed using the generalized score statistic [59] for
paired analyses or a proportions test for unpaired analyses. All confidence intervals (CI)
are reported as two-sided binomial 95% confidence intervals. All uses of the term “signif-
icant” in this manuscript are followed by the specific statistical criteria used to establish
significance.
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Sample Collection
Nasal epithelium samples collected from 28 
institutions as part of AEGIS clinical trials 
Gene Expression Proling
554 samples proled using Aymetrix Gene 1.0 ST 
microarrays
Quality Control
Microarray quality control of 523 samples using the 
ArrayQualityMetrics R-package (9 total metrics)
31 samples removed because of indeterminate 
cancer diagnosis at 1-year follow up
18 samples removed because they were agged 
as outliers by at least 3 microarray quality 
control metrics
Normalization & Batch Correction
505 nasal samples were considered suitable for data 
analysis. These samples were normalized using RMA 
and batch eects corrected for using ComBat
Training Set
AEGIS-1 nasal samples 
(n=375)
Validation Set
AEGIS-2 nasal samples 
(n=130)
Figure 2.1: Data acquisition and processing workflow. Nasal epithelial samples from
smokers with and without lung cancer were collected from 28 institutions across the U.S.,
Canada, and Europe as part of the AEGIS clinical trials. 557 samples were received by BU
and run on Affymetrix Gene 1.0 ST microarrays. 31 samples were lost due to indeterminate
cancer diagnosis at follow up. 18 samples were removed as part of the quality control
process. The 526 remaining samples were RMA normalized and batch-corrected together,
then separated into a training set (AEGIS-1, n=375) and validation set (AEGIS-2, n=130).
2.3 Results
2.3.1 Study Population
554 nasal epithelium samples were selected for microarray profiling from a larger pool of
RNA samples collected prospectively from patients with suspect lung cancer enrolled in
the AEGIS clinical trials [90]. 424 of these samples were from patients enrolled in the
AEGIS-1 trial and 130 were from patients in the AEGIS-2 trial (Figure 2.1). 31 patients
from the AEGIS-1 cohort had an indeterminate cancer diagnosis at one-year post-sample
collection or were lost to follow up and were removed from the study. Additionally, 18
nasal microarray samples from the AEGIS-1 dataset that did not meet minimum quality
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standards were also removed. No samples were removed from the AEGIS-2 dataset. The
remaining 375 samples from the AEGIS-1 cohort were used as a training set in which
all data analyses and biomarker derivation steps were performed, while the 130 samples
from the AEGIS-2 cohort were used solely to validate the predictive model (Table 2.1).
The distribution of cancer stages was slightly skewed toward later stage cancers in the
validation set (Table 2.2). Lung cancer patients tended to have larger nodules than patients
with benign diagnoses in both the training and validation sets (Table 2.3; p < 0.001 for
both comparisons) while patient age was significantly higher among cancer patients in the
training set (p < 0.001). The gene expression data from these samples has been deposited
in the NCBI Gene Expression Omnibus under accession number GSE80796.
2.3.2 Lung Cancer-Associated Gene Expression in Nasal Epithelium
We identified 535 genes whose expression was significantly associated with cancer status
in our training set (p < 0.001) (Figure 2.2 and Appendix B). Genes down-regulated in
patients with lung cancer were enriched for genes associated with DNA damage, regulation
of apoptosis, and processes involved in immune system activation including the interferon-
gamma signaling pathway and antigen presentation (Table 2.4). Among genes that were up-
regulated in lung cancer patients, we found enrichment for genes involved in endocytosis
and ion transport (Table 2.4). A complete list of significantly enriched pathways and GO
categories (FDR < 0.05) is shown in Appendix C, Appendix D, and Appendix E.
2.3.3 Similarities in Nasal and Bronchial Cancer-Associated Gene Expression
To determine if a shared pattern of cancer-related gene expression might exist between the
nose and bronchus, we leveraged microarray data from 299 bronchial epithelium samples
obtained from AEGIS-1 patients [114]. 157 of the 299 bronchial samples came from the
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Table 2.1: Clinical and demographic characteristics of patients who contributed nasal ep-
ithelial samples
Characteristic
AEGIS-1
Training Set
(n=375)
AEGIS-2
Validation Set
(n=130)
Cancer Status - no.*
Lung Cancer 243 66
Benign Disease 132 64
Smoking Status - no.
Current 140 46
Former 235 84
Gender - no.
Male 237 80
Female 138 50
Cumulative Smoke Exposure (SD; n) - pack-yr. 39.0 (26.9; 371) 34.8 (30.7; 130)
Time Since Quit (SD; n) - yr. 7.6 (12.9; 309) 9.4 (13.4; 120)
Age (SD) - yr. 59.5 (10.4) 61.7 (11.5)
Lesion Size - no.
≥ 3cm 171 59
< 3cm 142 54
Infiltrates 44 17
Unknown 27 0
Lesion Location - no.
Central 134 55
Peripheral 114 31
Central and Peripheral 100 44
Unknown 18 0
Lung Cancer Histological Type - no.
Small-cell 40 8
Non-small-cell 200 58
Adenocarcinoma 90 29
Squamous 72 17
Large-cell 9 4
Not Specified 29 8
Unknown 3 0
Diagnosis of Benign Condition - no.
Infection 36 7
Sarcoidosis 21 12
Other 48 15
SD indicates standard deviation; n indicates number of patients with clinical data available
*p-value < 0.05 by Fisher Exact
†Calculated as non-small cell vs small cell
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Figure 2.2: Characterization of 535 cancer-associated nasal epithelial genes in the
training set. 535 genes were differentially expressed by cancer status in the nasal training
set (p < 0.001) using a linear model that included cancer status, smoking status, pack years,
gender, age, and RIN as covariates. These genes were grouped into two co-expression
clusters by unsupervised hierarchical clustering. Unsupervised hierarchical clustering of
patients across these genes revealed two primary patient clusters.
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Nasal Sample 
Only
(n=218)
Both Nasal & 
Bronchial 
Samples
(n=157)
Bronchial 
Sample Only
(n=142)
Figure 2.3: Distribution of matched AEGIS-1 nasal and bronchial epithelial samples.
Of the 375 patients in the nasal training set, 157 had a matched bronchial epithelium sample
profiles as part of the study by Whitney et. al. The remaining 218 patients only had a nasal
sample profiled as part of this study. The clinical model was derived using the union set of
these samples (n = 517).
same patients as those in our nasal training set (Table 2.5; Figure 2.3). GSEA [98] revealed
(Figure 2.4, part A) that the genes up-regulated in nasal epithelium of patients with lung
cancer were amongst the genes most up-regulated in bronchial epithelium of patients with
cancer (p < 0.001) and that a similar relationship exists for genes down-regulated in pa-
tients with cancer between the nose and bronchus (p < 0.001). The expression of the most
concordantly differentially expressed genes are shown in Figure 2.4, part B and highlighted
in Appendix B.
To further explore the hypothesis of a shared field of nasal and bronchial lung cancer-
associated injury, we examined the nasal expression of 232 genes with lung-cancer associ-
ated expression in bronchial epithelium [114]. Whitney et al. grouped these genes into 11
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Genes down regulated in the presence of lung 
cancer in nasal epithelium
Down regulated 
genes in bronchial 
epithelium
Up regulated 
genes in bronchial 
epithelium
Samples
G
enes
Samples
Genes up regulated in the presence of lung 
cancer in nasal epithelium
Nasal epithelium (n=375) Bronchial epithelium (n=299)
Patient Cluster 1 Patient Cluster 2
Gene Expression (z-score)
-2 +2
Cancer BenignCore Enrichment
A B
Figure 2.4: Concordance between cancer-associated gene expression in bronchial and
nasal epithelium. A) The 535 genes with cancer-associated expression in nasal epithe-
lium were split into up- and down-regulated gene sets and we examined their distribution
within all genes ranked from most down regulated (left) to most up regulated (right) in the
bronchial epithelium of patients with cancer using GSEA. We found that the genes with in-
creased expression in nasal epithelium are enriched among the genes that are most induced
in the bronchial epithelium of patients with cancer (top; p < 0.001) while the reverse was
true for genes with decreased expression in nasal epithelium (bottom; p < 0.001). Genes
included in the core enrichment are shown in the green box. B) Heatmaps and hierarchical
clustering of the core enrichment genes in nasal (left) and bronchial (right) samples.
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clusters, and we found that the mean expression of 8 of the 11 clusters was significantly as-
sociated with lung cancer (p < 0.05) in our training set (Table 2.6); including gene clusters
enriched for genes involved in cell cycle, response to retinoic acid, and the innate immune
response. Based on the concordant expression of cancer-associated genes in bronchial and
nasal epithelium, we computed a “bronchial” lung cancer classifier score [114] for the nasal
training set samples and found that they were highly correlated with the scores computed
from matched bronchial samples (R = 0.70, p  0.001, n = 157) (Figure 2.5). Taken
together, these results suggest that lung cancer-associated gene expression differences are
similar in nasal and bronchial epithelium.
2.3.4 Nasal Gene Expression as an Independent Predictor of Lung Cancer Status
To determine if nasal gene expression could serve as a predictor of lung cancer status, we
selected the 30 most significantly differentially expressed genes (p  0.001) from among
the 535 genes with cancer-associated nasal gene expression for use in a weighted-voting
biomarker Appendix F. The biomarker panel size of 30 genes was chosen as the smallest
number of genes that achieved maximal performance in cross-validation. This biomarker
had an AUC of 0.69 (p  0.001, n = 375, 95% CI 0.63 to 0.75) in cross-validation in
the training set. 22 of the 30 genes were also significantly correlated between matched
bronchial and nasal samples (mean R = 0.29 [0.16, 0.49], p < 0.05).
In order to evaluate the potential for the nasal gene-expression biomarker to add to
clinical risk factors for lung cancer detection, we developed a clinical risk factor model
and tested whether incorporating the gene-expression biomarker enhances its performance.
In choosing which clinical risk factors to include, we relied on a study in which Gould
et al. identified smoking status, time since quit, age, and mass size as important clinical
risk factors of lung cancer for patients with solitary pulmonary nodules [39]. Patient age,
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Figure 2.5: Correlation of bronchial genomic classifier in matched nasal and bronchial
epithelium samples. Bronchial genomic classifier scores in matched nasal (y-axis) and
bronchial (x-axis) samples (n=157). The scores from both tissues were significantly corre-
lated (R=70, p 0.001). The vertical and horizontal lines indicate the cut-point for binary
classification reported by Whitney et al. Cancer samples are shown in green and benign
samples are shown in grey.
21
smoking status (current, former), time since quit (≤ 15 years, > 15 years, unknown), and
categorized mass size (< 3cm, ≥ 3cm, infiltrates) were used to create a clinical risk factor
model for lung cancer using logistic regression. The training set for this model consisted
of the nasal training set used to derive the gene expression classifier as well as clinical
data from an additional 142 patients from the AEGIS-1 cohort for a total training set of
517 patients for the clinical model (see Figure 2.3). A clinicogenomic logistic regression
model that incorporated the clinical factors and the nasal gene expression classifier score
was derived in the 375 training set samples with nasal gene expression.
The performance of the clinical and clinicogenomic models was evaluated using an in-
dependent set of nasal samples (n = 130) from the AEGIS-2 clinical trial that were not used
in the development of the classifier. The clinicogenomic model yielded an AUC of 0.81
(95% CI, 0.74 to 0.89) in the validation set which was significantly higher than the AUC
of 0.74 (95% CI, 0.66 to 0.83) achieved by the clinical risk-factor model alone (p = 0.01)
(Figure 2.6). Operating points for binary classification were chosen to maximize training
set sensitivity with specificity ≥ 50% for both models. The addition of cancer-associated
gene expression to the clinical risk-factor model increased sensitivity from 0.79 (95% CI,
0.67 to 0.88) to 0.91 (95% CI, 0.81 to 0.97) (p = 0.03) and negative predictive value from
0.73 (95% CI, 0.58 to 0.84) to 0.85 (95% CI, 0.69 to 0.94) (p = 0.03; Table 2.7). The
negative likelihood ratio of the clinicogenomic classifier was consistent between training
(0.18; 95% CI 0.12 to 0.28) and validation (0.18; 95% CI 0.08 to 0.39) sets. Additionally,
the clinicogenomic model had a negative predictive value of 0.85 (95% CI 0.65 to 0.96)
and a negative predictive value of 0.93 (95% CI 0.66 to 1.00) in subjects with either lesion
size < 3cm or peripheral lesions respectively (Table 2.8).
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Figure 2.6: Clinicogenomic and clinical classifier performance in the validation set.
Shown are the receiver-operating characteristic curves for the clinicogenomic (blue) and
clinical (red) classifiers in the independent AEGIS-2 validation set. The area under the
curve (AUC) was 0.81 (95% CI 0.74 to 0.89) for the clinicogenomic classifier and 0.74
(95% CI 0.66 to 0.83) for the clinical classifier. The difference between ROC curves was
significantly different (p = 0.01).
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2.4 Discussion
In this study, we have established that the lung cancer-associated airway “field of injury”
detectable in bronchial airway epithelium [95, 7, 114] extends to the nasal epithelium.
These findings generally strengthen the “field of injury” hypothesis in which there are gene
expression alterations in normal-appearing epithelial cells throughout the entire airway of
smokers with lung cancer; and intriguingly, suggest the potential for lung cancer biomark-
ers based on nasal epithelial gene expression.
While previous studies have validated the existence of bronchial airway gene expression
alterations in patients with lung cancer and demonstrated their clinical utility in lung cancer
detection [90], little is known about physiological processes responsible for this “field of
injury”. One hypothesis for the presence of lung cancer-associated alterations in nasal and
bronchial gene expression is that the subset of smokers who develop lung cancer exhibit a
distinct genomic response to tobacco smoke exposure throughout all airway epithelial cells,
consistent with the “etiological field effect” described by Lochhead et al. for colon and
other cancer types [63]. This paradigm suggests that the airway gene-expression signature
is a risk marker for lung cancer as opposed to a direct consequence of the presence of lung
cancer based on local or systemic factors produced by the tumor or its microenvironment
(i.e. the “conventional field effect” defined by Lochhead et al. [63]). Consistent with
the etiological field effect hypothesis, we observed a concordant down-regulation of genes
associated with immune system activation in patients with lung cancer in both bronchial
and nasal epithelium, which might suggest an impaired immune response sets the stage
for tumorigenesis in the lung microenvironment. Alternatively, despite the distance to the
tumor, these cancer-associated gene expression differences may be a direct result of factors
secreted by the tumor or its microenvironment, or some other consequence of the presence
of the tumor consistent with the “conventional field effect” described above.
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Mechanistically, it is intriguing that a number of genes with important roles in cancer-
related processes are among the differentially expressed genes. Of the genes that were
down-regulated in patients with lung cancer, CASP10 and CD177 were among the most
correlated genes between bronchial and nasal epithelium and are associated with the induc-
tion of apoptosis and activation of the immune response, respectively. We also identified
a number of genes involved in the p53 pathway that were down-regulated in patients with
lung cancer including BAK1, ST14, CD82, and MUC4. BAK1 is associated with the in-
duction of apoptosis [83, 41] and has been previously shown to be down regulated in the
tumors of patients with NSCLC [91]. ST14 has been described as a tumor suppressor in
breast cancer and its over expression associated with the inhibition of tumor cell migration
and cell invasion [113]. Down-regulation of CD82, which is a metastasis suppressor in
prostate cancer [30], has been shown to be correlated with poor survival in patients with
lung adenocarcinoma [2]. MUC4, whose down-regulation has been associated with in-
creased tumor stage and poorer overall survival has also been shown to play an oncogenic
role in multiple cancers and is a tumor suppressor in NSCLC, acting as a modifier of p53
expression [64].
From a clinical perspective, we found that the addition of lung cancer-associated gene
expression to established clinical risk factors improved the sensitivity and negative pre-
dictive value for detecting lung cancer which are the key performance metrics for driving
potential clinical utility in this setting (e.g. allowing physicians to avoid unnecessary in-
vasive procedures in those with benign disease). This provides the first proof-of-concept
for the use of nasal gene expression for lung cancer detection. We elected to establish the
presence of a nasal field of lung-cancer associated injury using samples from the AEGIS
trial given the unique availability of matched bronchial samples, despite the fact that these
patients were undergoing bronchoscopy for suspect lung cancer. The demonstration of the
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added value of nasal gene expression for lung cancer detection in this setting sets the stage
for the development of nasal gene expression biomarkers for lung cancer in other clinical
settings where bronchoscopy is not frequently used because of lesion size/location, risk of
complications, or cost. In particular, it will now be of interest to develop nasal biomark-
ers for patients with small peripheral nodules found incidentally or via screening as our
current bronchoscopy-based cohort is enriched for patients with centrally-located lesions.
In the clinical setting of patients with small peripheral nodules, we envision that a nasal
biomarker for lung cancer with a low negative likelihood ratio (on par with the NLR we
observed for the nasal biomarker in the AEGIS samples) could be used to identify nodule
patients who are at low risk of malignancy and can be managed by CT surveillance.
The importance and potential impact of this study derive from several key strengths.
First, the patients came from a large number of academic and community hospitals and
reflect a variety of practice settings and different geographical locales; thus the diversity of
alternative benign diagnoses is represented. Second, the training and validation sets came
from two separate clinical trials which minimizes the potential for the model to depend on
locally confounding variables. Third, the samples were prospectively collected and cancer
status was unknown at the time of collection. Fourth, we have shown that nasal gene
expression identifies a source of lung cancer risk that is independent of major clinical risk
factors.
Together, the findings demonstrate the existence of a cancer-associated airway field of
injury that can be measured in nasal epithelium; a biosample that can be collected non-
invasively with little instrumentation or advanced training. Moreover, we find that nasal
gene expression contains information about the presence of cancer that is independent of
standard clinical risk factors, suggesting that nasal epithelial gene expression might aid in
lung cancer detection. These findings, in particular the high NPV of the nasal clinicoge-
26
nomic biomarker, suggest the potential to rule out lung cancer and set the stage for efforts
to develop nasal gene expression biomarkers that might have clinical utility in avoiding un-
necessary invasive procedures in settings where bronchoscopy is not used as a diagnostic
procedure, including small peripheral nodules.
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Table 2.2: Stage data on patients diagnosed with primary lung cancer
AEGIS-1
Training Set
(n=243)
AEGIS-2
Validation Set
(n=66)
Lung Cancer Stage
NSCLC* 200 58
1a, 1b 44 6
2a, 2b 13 4
3a, 3b 44 19
4 66 25
Uncertain 33 4
SCLC† 40 8
Extensive 18 8
Limited 16 0
Uncertain 6 0
Unknown 3 0
*p = 0.04 calculated as AEGIS-1 NSCLC stage vs AEGIS-2 NSCLC stage
†p = 0.02 calculated as AEGIS-1 SCLC stage vs AEGIS-2 SCLC stage
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Table 2.4: Functional characterization of genes with cancer associate expression in nasal
epithelium
Down-Regulated Genes (n=492) FDR
DNA Damage
Signal transduction involved in mitotic DNA integrity checkpoint
(GO:1902400) <0.001
Ubiquitin-dependent degradation of Cyclin D1 (Reactome) <0.001
Regulation of Apoptosis (Reactome) <0.001
G1/S DNA damage checkpoints (Reactome) <0.001
Immune System Activation
Antigen presentation and processing of exogenous antigens
(GO:0019884) <0.001
Interferon-gamma signaling (Reactome) <0.001
Up-Regulated Genes (n=43) FDR
Ion Transport
Response to magnesium ion (GO:0032026) 0.01
Regulation of endocytosis (GO:0030100) 0.01
Positive regulation of release of calcium ion into cytosol (GO:0010524) 0.02
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Table 2.5: Clinical and demographic characteristics of patients with matched nasal and
bronchial epithelial samples included in this study.
Characteristic
Matched
Nasal Samples
(n=157)
Non-matched
Nasal Samples
(n=218)
Cancer Status - no.*
Lung Cancer 97 146
Benign Disease 60 72
Smoking Status - no.
Current 53 87
Former 104 131
Gender - no.
Male 104 85
Female 53 133
Cumulative Smoke Exposure (SD) - pack-yr. 37.8 (24.7) 39.9 (28.4)
Time Since Quit (SD) - yr. 8.1 (12.6) 7.0 (13.2)
Age (SD) - yr. 59.6 (11.2) 59.5 (9.8)
Lesion Size - no.
≥ 3cm 66 105
< 3cm 68 74
Infiltrates 17 27
Unknown 6 12
Lesion Location - no.
Central 55 79
Peripheral 51 63
Central and Peripheral 42 58
Unknown 9 18
Lung Cancer Histological Type - no.
Small-cell 14 26
Non-small-cell 83 117
Adenocarcinoma 41 49
Squamous 30 42
Large-cell 3 5
Not Specified 9 20
Unknown 0 4
Diagnosis of Benign Condition - no.
Infection 15 21
Sarcoidosis 11 10
Other 18 30
SD indicates standard deviation
* no significant differences were observed between matched and nonmatched samples
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Table 2.6: Aggregate expression of lung cancer gene clusters from bronchial epithelium in
nasal epithelial samples
Cluster Function
Number
of
Probesets
Direction
in
Cancer
Association
with
Cancer†
1* Innate immune 25 Down <0.001
2* Mitotic cell cycle 47 Down 0.05
3 Inflammation 45 Down 0.83
4* Resp. retinoic acid/cell cycle 34 Up 0.004
5 — 10 Up 0.36
6 — 21 Down 0.02
7* Submucosal gland markers 20 Up 0.01
8 — 15 Up 0.003
9* Xenobiotic detoxification 7 Down 0.15
10* Cartilaginous markers 4 Down 0.05
11 — 1 Down 0.03
*In bronchial genomic classifier described by Whitney et al.
†p-value of t-test measuring the difference in mean average expression of all genes in a cluster
between cancer and benign nasal samples in the AEGIS-1 cohort
Table 2.7: Classifier performance in the validation set (n=130)
Clinical Model
(95% CI)
Clinicogenomic Model
(95% CI)
AUC* 0.74 (0.66-0.83) 0.81 (0.74-0.89)
Sens* 0.79 (0.67-0.88) 0.91 (0.81-0.97)
Spec 0.58 (0.45-0.70) 0.52 (0.39-0.64)
NPV* 0.73 (0.58-0.84) 0.85 (0.69-0.94)
PPV 0.66 (0.54-0.76) 0.66 (0.55-0.76)
ACC 0.68 (0.60-0.76) 0.72 (0.63-0.79)
*p < 0.05
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Chapter 3
RABBIT: AN R-PACKAGE FOR BIOMARKER DISCOVERY IN
HIGH-DIMENSIONAL GENOMIC DATA
3.1 Introduction
The use of genomic data to predict clinical endpoints is well established. Of particular
interest during the past two decades has been the development of predictive models based
on gene expression microarray data. Microarray studies are typically designed to compare
two or more biological conditions and usually provide expression measurements on tens
of thousands of transcripts or genes at a time. The applications of these data are vast, and
include risk assessment, early detection and diagnosis of disease, prognosis, and treatment
guidance [89]. In 1999, Golub et al. published a landmark study describing a mathematical
model based on gene microarray data that could differentiate between patients with acute
myeloid leukemia and acute lymphoblastic leukemia [38]. This work served as the first
proof-of-concept for the use of microarray data to predict a clinical endpoint and led to the
development and publication of a number of molecular classifiers [109, 110, 21, 27, 112,
81]. The primary goal of these studies and others has been to gain molecular insight into
patients' disease with the intent of influencing or personalizing treatment decisions.
Over the past decade and a half, the number of publications focused on microarray-
based clinical research has grown exponentially [32]. However, despite the promise of
this technology, very few studies have produced biomarkers that meet the required level of
evidence to be implemented in the clinic [33]. This has resulted in both unrealistic hype
and excessive skepticism about the technology as a whole and highlights a critical need for
better processes to develop, validate, and publish microarray-based predictive models. A
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number of factors contribute the success or failure of a biomarker including study design,
data quality, methods and protocol reporting, and team proficiency.
Rigorous study design is the foundation for the development of a clinically actionable
biomarker and typically includes recruitment of a homogenous population of patients in the
specific clinical setting in which the test is intended to be used. Ideally, complete clinical
annotation on each patient enrolled in the study will be available and care will be taken
to minimize batch effects induced during recruitment, collection, and processing of patient
samples. Too heterogeneous a population and incomplete clinical annotation can lead to
biases in the data that are not accounted for and may result in false positive findings of
association with the clinical endpoint of interest. Furthermore, batch effects, both known
or unknown, that are induced as a result of improper study design may render the data
uninterpretable if the effect of batch cannot be dissociated from the clinical outcome vari-
able. Data quality is often directly related to study design as well with poor quality data
dramatically hindering the reproducibility of the study.
Issues with methods and protocol reporting have also been recognized as a major hur-
dle in translating biomarker research into the clinic [72] and have led to the development
of the REMARK [67] and STARD [12] reporting guidelines for prognostic and diagnostic
markers, respectively. These guidelines, which have become a requirement for publica-
tion in many journals, provide recommendations on how to report the specific details of
study design, patient and sample characteristics, and any analytical and statistical methods
employed so that the findings presented in the manuscript are reproducible. Adherence to
these guidelines, however, is poor to moderate at best [52], with only approximately 20%
of published articles reporting all required fields according to some reports [43]. The lack
of clarity regarding the methodological details behind the derivation of a biomarker often
results in irreproducibility of the findings of the paper and render the results uninterpretable.
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Lastly, many studies have concluded that team proficiency influences the performance
and longevity of a biomarker model [89, 101]. The process of developing a mathematical
model from gene expression microarray data is complex and often includes a number of
unique data processing steps for which there are countless methods available with varying
degrees of effectiveness given a particular dataset. It is not surprising, then, that experi-
enced teams whom understand the intricacies of this process are less prone to error than
inexperienced teams. For example, a typical workflow will include data preprocessing, di-
mensionality reduction, feature selection, biomarker panel size selection, and training of
a classification algorithm. It is the responsibility of the developer to evaluate and select
the best methods to use at each step in this process. More often than not, however, in-
experienced biomarker developers make decisions about which method to use a priori or
only consider methods with which they are familiar and have experience. This inherently
limits the final model to one of only a few possibilities, all of which are likely to be sub-
optimal for the problem at hand. Furthermore, errors implementing or evaluating any of
these models can lead to inflated performance estimates and irreproducible results. More
proficient teams will often consider a number of different techniques and will evaluate them
against each other in an unbiased manner [102], ultimately settling on a method that yields
near-optimal performance for the given dataset. Here, we seek to define and implement a
solution to the challenge of identifying optimal model development parameters in order to
build and evaluate biomarkers in any given dataset.
In order to find the set of optimal biomarker model development parameters, several
methods must be considered at each step in the model development process. This requires
the developer to understand not only the importance of each step in the process, but also
how to properly implement, compare, and contrast each method. A useful strategy for
comparing the performance of several model configurations is via cross-validation which
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allows each model to be trained and evaluated on a single dataset and can provide an unbi-
ased estimate of how the model will perform on independent data.
Recent efforts on behalf of the open-source software community have led to the devel-
opment of tools that provide access to computational methods that can be used to evaluate
classification models in cross-validation. In particular, the caret R-package [54] provides
a uniform and intuitive interface to hundreds of classification algorithms and contains em-
bedded methods for hyper-parameter tuning and cross-validation. While caret does contain
a small number of formal feature selection methods, the package was not designed to be
used with high dimensional genomic data, such as microarray data, and is primarily focused
on the training of robust classifiers. Furthermore, there are no pre-built methods available
to systematically compare the performance of models that use various feature selection and
classification algorithms.
Another R-package, maPredictDSC [102], has been developed which loosely attempts
to streamline the model development process. maPredictDSC provides an implementa-
tion of the approach used by the winning team in the IMPROVER Diagnostic Signature
Challenge. Provided within the package is a pipeline that will build models using various
normalization algorithms (RMA, GCRMA, and MAS5), filtering methods (mttest, ttest,
wilcox), panel sizes, and classifiers (LDA, KNN, SVM). While this pipeline does support
some user-based customization, such as the ability to activate and deactivate certain meth-
ods, users cannot add their own methods or add a new step to the pipeline, such as a batch
correction technique, which inherently limits the broad application of this approach.
Given the complexity and challenges of biomarker development and the lack of tools
available in the open-source community, there is a clear need for tools that facilitate the pro-
cess end-to-end. Such tools should provide users with a framework for building biomarkers
from high dimensional data which can be used to identify optimal modeling parameters ir-
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respective of the dataset. Furthermore, these tools should automatically enforce best prac-
tices and be accessible to both novice and expert users.
To address these needs, we have developed rabbit, an R-package for biomarker de-
velopment in high dimensional genomic datasets. The rabbit package provides a powerful
biomarker development pipeline which evaluates the performance of 840 unique models on
a given dataset. The pipeline includes a wide range of methods including those for feature
filtering, feature selection, panel size selection, and classification. This pipeline is accessed
through a single, intuitive run function and can be customized to suit the user's needs. The
package also provides a number of utility functions which can be used to create custom
biomarker pipelines from scratch or to customize existing pipelines. The rabbit package is
freely available at https://github.com/jperezrogers/rabbit.
3.2 Implementation
3.2.1 Package Structure
The rabbit package is built on an object-oriented programming framework using the open
source R statistical computing environment [103]. R6 class structure was used to create
three new classes (Task, Module, and Pipeline; discussed below). R6 was chosen in place
of R's S3 and S4 reference class structure because of its efficiency and lack of dependence
on S4 classes or the methods package [16]. The package was designed based on published
style guides [58, 115] and in compliance with the Bioconductor repository contributor poli-
cies [44].
3.2.2 Terminology & Style
Herein, classes will be referred to by their formal name with the first letter of the class name
capitalized (e.g. Task class). Objects will be referred to by the class name from which they
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are derived with the first letter of the class name in lower case (e.g. task object).
3.2.3 Concept
The biomarker model development process (introduced above) is complex and includes a
number of distinct steps such as data preprocessing, dimensionality reduction, feature se-
lection, and classification. Many different methods exist for each step in this process and
it is desirable to select the ideal combination of methods that will achieve optimal perfor-
mance for a given dataset. The systematic evaluation of all permutations of methods can be
thought of as a computational pipeline. Each step in the model development process (e.g.
feature selection) can then be thought of as a module, or a collection of similar methods
that achieve roughly the same goal. Finally, the specific methods that are applied to the
data can be thought of as tasks. Thus, tasks with similar function can be grouped together
into modules and modules can be strung together one after another in a particular order to
form a pipeline. A pipeline can then be thought of as a tool that can be used to evaluate
the performance of all possible models, where a model is a unique combination of tasks
selected from each module. The purpose of this package is to provide this exact type of
tool to help users identify the optimal combination of model development parameters that
will achieve maximal performance on a given dataset.
3.2.4 Task Class
The Task class is used to create objects that contain all of the information required to ex-
ecute a discrete function on a set of data within the setting of a biomarker pipeline. The
Task class is characterized by five public members including label, method, datatype,
parameters, libraries, and control. The label and method members are required
input parameters upon instantiation of a task object while parameters, libraries, and
39
control are optional. The label member provides a task with a name that is used
throughout the pipeline to reference that specific task. The method member provides a
task with a specific function to perform on a set of data. The required input parameters
and output format for this function are dependent upon the type of module the task is to be
added to and are discussed in detail below in the context of modules (Section 3.2.7.5).
The parameters member is used to allow the user to provide additional input parame-
ters to a task's method function in addition to those that are already required. This member
specifies the argument name, class, and textual label of any additional parameters; infor-
mation that is subsequently used to validate the datatype and value that will be passed to
the task's method function. The control member is used to provide a range of values to
be passed to the method via the additional parameters that were specified in parameters.
Finally, the libraries member is used to name any required libraries that may be invoked
in the execution of the method.
3.2.5 Module Class
The Module class provides a framework for grouping tasks with a similar function and
purpose together. Upon instantiation, every module object is assigned a label and type.
There are four different types of modules (M1, M2, M3, and M4) which are defined by the
input and output requirements of their tasks (Figure 3.1). All tasks added to a given module
must conform to the input/output requirements of that particular module type. The input
and output of each module is standardized to facilitate customization while maintaining
control of the structure and implementation of the various models within a pipeline.
Type M1 modules store tasks that take in a numerical matrix x and output a numerical
matrix. These tasks may also take in phenotype information in the form of an R data frame
using the input parameter data. M1 modules are used primarily for unsupervised processes
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Figure 3.1: Input and output specifications of each module type. There are four differ-
ent types of modules that can be added to a pipeline. Each module is defined by a set of
input and output parameters. M1 modules store tasks that take in a numerical matrix and
(optionally) a data frame of phenotype annotation and output a numerical matrix. M2 mod-
ules store tasks that take in a numerical matrix, response variable, and (optionally) a data
frame of phenotype annotation and output a list containing a numerical matrix and (option-
ally) a ranked list. M3 modules store tasks that take in a numerical matrix and (optionally)
a ranked list and output a numerical matrix. Finally, M4 modules store tasks that take in a
numerical matrix, response variable, and (optionally) a data frame of phenotype annotation
and output a list containing classifier scores and classifications computed on the internal
test set.
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(those that do not use the response variable y) that are applied to the expression matrix.
Type M2 modules store tasks that take in a numerical matrix x, a response variable y,
and optionally, a phenotypic data frame data. These tasks output a numerical matrix and
optionally, a ranked list. Unlike M1 modules, M2 modules are designed for supervised
processes (those making use of the response variable y). Type M3 modules store tasks take
in a numerical matrix x and, optionally, a ranked list rank. M3 modules are primarily
used to select genes from a pre-defined ranking. Finally, type M4 modules store tasks
take in a numerical matrix x, response variable y, test dataset testdata, and optionally, a
phenotypic data frame data. M4 modules reside exclusively at the end of a pipeline and
are used to implement classification tasks. Tasks in M4 modules must output a list with
two named elements: score and class. Score is a numerical vector of prediction scores
computed on the samples in testdata. Class is a numerical vector of binary classifications
for these same samples.
3.2.6 Pipeline Class
The Pipeline class provides a framework for grouping a set of modules together and evalu-
ating all permutations of tasks in cross-validation. The Pipeline class has four public mem-
bers including label, cv, p, and nfolds. As in the Task and Module classes, the label
member provides a name for the pipeline object. The other three members are used to con-
figure the cross-validation scheme to be used when the pipeline is run. Specifically, cv is
used to specify the cross-validation routine, p to define the fraction of samples to include in
the internal training set, and nfolds to specify the number of iterations of cross-validation
to conduct.
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3.2.7 Utility Functions
The rabbit package provides a set of utility functions that allow the user to easily add to,
modify, and customize existing pipelines as well as to construct their own pipelines from
scratch. Each of these utility functions are summarized in Table 3.1 and described in detail
below.
3.2.7.1 newPipeline()
The newPipeline function is used to create a new pipeline object from the Pipeline class.
The only required argument to the function, by default, is the label parameter which gives
the pipeline a name. Three additional arguments, cv, p, and nfolds, are available which
allow the user to customize the cross-validation scheme that will be used when the pipeline
is run. Input parameter cv allows the user to define the cross-validation methodology to
be used and is set to leave-group-out cross-validation (‘lgocv’) by default. Other cross-
validation schemes available in the rabbit package include k-fold cross-validation (‘cv’),
leave-one-out cross-validation (‘loocv’), and bootstrapped cross-validation (‘boot’). Ar-
gument p allows the user to define the fraction of samples that should be included in the
training set. This parameter is only used if cv is set to ‘lgocv’. The final argument is
nfolds which defines the number of iterations of cross-validation to perform. This pa-
rameter is only used if cv is set to ‘lgocv’ or ‘boot’ given that the other schemes, ‘cv’ and
‘loocv’, have a pre-determined number of iterations.
3.2.7.2 addModule()
The addModule function allows the user to add a new module to an existing pipeline.
The function has three arguments: pipeline, type, and label. The pipeline argument
specifies the pipeline object to which the new module will be added. The type argument
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Table 3.1: Rabbit utility functions
Function Description Arguments Returned
newPipeline create a new pipeline
object
label, cv, p,
nfolds
object of class
Pipeline
addModule add a new module to a
pipeline
pipeline, label,
type
—
deleteModule delete a module from a
pipeline
pipeline, label —
orderModules reorder modules within
a pipeline
pipeline, order —
addTask add a task to a module
within a pipeline
pipeline, module,
label, method,
parameters,
control, libraries
—
deleteTask delete a task from a
module within a
pipeline
pipeline, module,
task
—
activateTask activate a task or tasks
within a pipeline
pipeline, module,
task
—
deactivateTask deactivate a task or
tasks within a pipeline
pipeline, module,
task
—
getCall return the function call
used to add a task to a
pipeline
pipeline, module,
task
A list
update update a pipeline's
cross-validation
configuration
pipeline, what,
value
—
summary print out a useful
summary of a pipeline
object
pipeline, level printed message
run run a pipeline pipeline, x, y,
data, rank,
outputdir, iter,
seed, force,
verbose,
exitOnError,
returnTraceback
—
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must be a character string and be set to one of M1, M2, or M3 which will define the type
of module to be added. Discussed above are the details regarding the different types of
modules. The newModule function is restricted to only the first three types of modules
rather than all four because new pipelines are instantiated with an M4 module already in
place. Given that there can be only one and only one “classification” module per pipeline,
there is no need to be able to add a new M4 module. There is no limit on the number of
modules that can be added to a pipeline nor are there limits on the diversity of the modules
within a pipeline. However, an error will occur if one tries to add a new module to a pipeline
that already contains a module with the same label. Each module in a pipeline must have a
unique label.
3.2.7.3 deleteModule()
The deleteModule function is used to permanently remove a module from a pipeline. The
function has two arguments, pipeline and module. The pipeline argument specifies the
pipeline object from which the module is to be removed. The module argument specifies
the label of the module to be deleted. The value provided to the module argument must be
a character string of length one and must match one of the module labels in the pipeline
specified by the pipeline argument. Deletion of a module from a pipeline will result in the
deletion of all tasks included in that module; a procedure that cannot be undone. Given that
all pipelines constructed by the rabbit package must terminate with classification module,
modules of type M4 cannot be deleted using the deleteModule function.
3.2.7.4 orderModules()
The orderModules function is used to rearrange modules within a pipeline. This func-
tion takes two arguments: pipeline and order. The pipeline argument specifies the
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pipeline object in which the modules are to be rearranged. The order argument is a char-
acter vector of module labels where the order of labels specifies the new order of modules
to be set in the pipeline. All module labels in a pipeline must be named in order. Omis-
sion of any module labels will result in an error. Consistent with the remarks above, the
classification module cannot be moved from the last position in the pipeline. As a result,
“classification” must be the last module named in the order argument.
3.2.7.5 addTask()
The addTask function is used to add a new task to a module within a pipeline. The
addTask function has a number of required and optional arguments. Required arguments
include pipeline, module, label, and method. Optional arguments include parameters
and control. The pipeline and module arguments specify the pipeline object and la-
bel of the module to which the new task is to be added. The label argument must be a
character string which provides a name for the task. The method argument must be an R
function with specific inputs and outputs that are dictated by the type of module specified
in the module argument. The specific input/output requirements for the function specified
in the method argument are shown in Table 3.1 and described below.
For tasks added to type M1 modules, the function provided to the method argument
must take in as input a gene expression matrix x with samples in columns and genes in
rows. Optionally, this function can also take in phenotype data in the form of an R data
frame with samples in rows and covariates in columns using the input variable data. This
data frame must have row names equal to the column names of the gene expression matrix
x. The function must output a similar gene expression matrix with the same column names
as the input but not necessarily the same number of rows.
For tasks added to type M2 modules, the function provided to the method argument
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must take in as input a gene expression matrix x (as above) and a response variable y. The
response variable must be a two-level factor with length equal to the number of columns
in x and cases and controls labeled as 1 and 0, respectively. As with M1 modules, this
function can also optionally take in phenotype data (as above) using the input variable
data. The function must output a similar gene expression matrix to that of x with the same
column names as the input but not necessarily the same number of rows. This function
can also optionally output a ranked list in the form of a numerical vector where each entry
corresponds to a respective row in the output gene expression matrix.
For tasks added to type M3 modules, the function provided to the method argument
must take in as input a gene expression matrix x (as above) and, optionally, a ranked list
rank. The ranked list should be a numerical vector with length equal to the number of rows
in x. The function must output a similar gene expression matrix to that of x with the same
column names as the input but not necessarily the same number of rows.
For tasks added to type M4 modules, the function provided to the method argument
must take in as input a gene expression matrix x (as above), a response variable y, and
a numerical matrix of test data testdata. As with M1 and M2 modules, this function
can also optionally take in phenotype data (as above) using the input variable data. The
response variable must be a two-level factor with length equal to the number of columns in
x and cases and controls labeled as 1 and 0, respectively. During the execution of a pipeline
run, the testdata input parameter is automatically populated by the pipeline to contain
the internal test set samples. The user should assume that testdata is a numerical matrix
with samples in columns and genes in rows and row names equal to those in the input
matrix x. Based on this assumption, the user will be able to produce the required output for
the function which should be a list with named elements score and class. The score element
must be a numerical vector of classifier scores with length equal to the number of columns
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in testdata. The class element, then, is the binarization of the classifier scores representing
a unique classification for each test set sample.
Beyond the required arguments, two optional arguments may be provided to the addTask
function. The parameters argument is an R data frame with three named elements: the
parameter name (parameter), the data type (class), and a textual label (label). For each
additional input parameter provided to the method beyond the required inputs, these three
element must be specified. Finally, the control argument to the addTask function is used
to specify alternative values for each of the additional input parameters specified in param-
eters. The control argument is a list where each element corresponds to an entry in the
‘parameter’ element of parameters. The value of each list item in control is dependent
upon the class of the variable to which the values will be passed, and should be consistent
with the ‘class’ element of parameters.
It is important to note that if a new task is added to a module within a pipeline where
a task with the same label already exists, the new task will automatically overwrite the
existing task. This action is not reversible and any information stored in the pipeline about
the previous task will be lost. Care should be taken to ensure that task labels are unique
and that the overwriting behavior is desired.
3.2.7.6 deleteTask()
The deleteTask function is used to remove a task from a module within a pipeline. The
function has three arguments: pipeline, module, and task. The pipeline and module
arguments specify the pipeline object and specific module label from which the task is
to be deleted. The task argument is a character string or character vector of task labels.
Multiple tasks at a time can be deleted from a single module, however tasks in different
modules must be deleted separately.
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3.2.7.7 activateTask()
Every task within a pipeline has an activity status that can be toggled on and off. When a
pipeline is executed, only active tasks are used while inactive tasks are not. The activateTask
function is used to turn tasks on. The function takes three arguments: pipeline, module,
and task. As above, the pipeline and module argument specify the pipeline object and
specific module in which to activate the task. The task argument must be a character string
or character vector of task labels in the same module. Multiple tasks from a single module
can be activated at a time, however tasks in different modules must be activated separately.
3.2.7.8 deactivateTask()
The deactivateTask function is used to turn tasks off. Inactive tasks are stored, but
are not called during the execution of a pipeline. The function takes three arguments:
pipeline, module, and task as described above. Multiple tasks from a single module can
be deactivated at a time, however tasks in different modules must be deactivated separately.
3.2.7.9 getCall()
The getCall function is used to return the function call that was used to add a particular
task to a pipeline. Adding a new task to a pipeline can be non-trivial given that the addTask
function has many arguments. The getCall function was designed to allow users to lever-
age existing code to modify existing tasks or develop entirely new ones. The function takes
the same three arguments as the above functions: pipeline, module, and task. The task
argument, in this case however, must be a character string of length one that specifies the
label of a task in the pipeline. The getCall function will return a list with seven elements
which include the pipeline object to which the task was added (pipeline), the label of the
task's parent module (module), the label of the task (label), as well as the method, parame-
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ters, control, and libraries arguments used to create the task. This list-style format can then
be used directly with the native R function do.call to re-execute the addTask call.
3.2.7.10 update()
The update function is used to modify the configuration parameters of a pipeline object.
The function takes three arguments: pipeline, what, and value. The pipeline argu-
ment specifies the pipeline object to which to make the change. The what argument is used
to specify the configuration parameter to modify. This argument must be a character string
and must be one of ‘label’, ‘cv’, ‘p’, or ‘nfolds’. The value parameter defines the new
value to be used for the configuration parameter specified in what.
3.2.7.11 summary()
The summary function is used to print useful information about a pipeline object to the
screen. The function takes two arguments, pipeline and level. The pipeline argu-
ment specifies the pipeline object to summarize and the level argument defines the type of
summary to display. The level parameter can be set to one of ‘overview’, ‘structure’, ‘de-
tailed’, or ‘active’. By default, level is set to ‘overview’ and the summary function will
print out a high-level summary of the pipeline object which includes the label, total number
of models, cross-validation method, number of folds (where applicable), and the training
set fraction (where applicable). When level is set to ‘structure’, the summary function
will print out the label of each module and its associated tasks. It is important to note that
only active tasks are displayed in the pipeline structure. Setting level to ‘detailed’ will
provide a more in-depth summary of the tasks in the pipeline including details about addi-
tional parameters and values passed to the method argument of each task. Finally, setting
level equal to ‘active’ will provide a summary of which tasks in a pipeline are active and
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inactive.
3.2.7.12 run()
The run function is used evaluate all of the models stored within a pipeline object on a set
of data in cross-validation. As models are evaluated, the function will write the resulting
scores and classifications to a designated output directory. The run function takes sev-
eral arguments including pipeline, x, y, data, rank, outputdir, iter, seed, force,
verbose, exitOnError, and returnTraceback. Arguments pipeline, x, and y are
mandatory. Arguments data and rank are conditionally mandatory, and all other argu-
ments are optional. The pipeline argument must be an object of class Pipeline. Argu-
ment x must be a numerical matrix of gene expression values with samples in columns and
genes in rows. The columns and rows of x must be named and must be unique. Argu-
ment y stores the response variable used for classification and must be a two-level factor
with length equal to the number of columns in x and cases and controls coded as 1 and 0,
respectively.
The data argument is used to provide the pipeline with phenotype data for each sam-
ple and must be in the form of an R data frame with samples in rows and covariates in
columns. This data frame must have the same number of rows as there are columns in x
and with samples assumed to be in the same order in both objects. The data argument is
conditionally mandatory for the run function in that it is only required if one or more tasks
in the pipeline makes use of the data input parameter in their method argument. If data
is required and not provided, an error message will be displayed and the user will have to
provide this information or modify their pipeline.
The rank argument is used to provide the pipeline with ranking criteria that can be
used to sort or select genes and must be in the form of a numerical vector with length equal
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to the number of rows in x. The rank argument is conditionally mandatory for the run
function in that it is only required if a type-M3 module precedes a type-M2 module in a
pipeline and the rank input parameter is used in at least one task's method argument in
the M3 module. Tasks added to type-M3 modules may take in a ranked list as part of their
method argument. If an M2 module does not exist immediately upstream of an M3 module,
the user must provide a ranked list to be input to the task within the M3 module.
The outputdir argument to the run function specifies where the output of the pipeline
run should be stored. The iter argument allows the user to run a specific iteration of cross-
validation rather than the entire procedure. This is parameter will be valuable if the user
wants to parallelize the cross-validation iterations across many machines. Related to the
iter argument is the seed argument. This argument allows the user to set the seed for
random number generation. When parallelizing cross-validation iterations, it is essential
that the user set a seed in advance so that any random partitioning of the data into internal
training and test sets is consistent regardless of the machine in which the process is being
carried out. If the seed is not set and cross-validation iterations are parallelized, there will
be no consistency between iterations and the results of the pipeline will be invalid and
uninterpretable.
The final four arguments to the run function are all logical in nature, taking values of
true or false. The force argument determines whether or not the pipeline should over-
write any existing result in the output directory. The verbose argument determines if the
pipeline should print messages to the screen as it runs. The exitOnError argument han-
dles the pipeline's behavior if an error occurs in one of the models. If true, when the pipeline
encounters an error, it will skip the model that caused the error and continue its evaluation
with the next model. If false, the pipeline will stop and exit. The returnTraceback ar-
gument handles how errors are reported when they occur in a pipeline run. If true and an
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error occurs, the pipeline will report back the traceback stack which the user can use for
debugging purposes. If false, the pipeline will be silent.
3.2.8 Stock Pipeline
The rabbit package is equipped with a stock implementation of a biomarker discovery
pipeline designed for use with microarray data and built using the tools discussed above.
The stock pipeline consists of four modules and fifteen tasks which were chosen to repre-
sent the most commonly used methods in the community as reported in the MAQC-II study
[89] (Table 3.2). The four modules include gene filtering, feature selection, biomarker
panel size selection, and classification and are shown in the context of the entire pipeline
in Figure 3.3. The Gene Filter module is the first module in the pipeline and is designed to
reduce the dimensionality of a microarray dataset using unsupervised techniques such as
variance and mean filters. These methods greatly reduce the inherent noise in the dataset
and provide downstream methods with a subset of genes that are most likely to contain
signal. The next module in the pipeline is the Feature Selection module which takes this
subset of genes and evaluates their association with the response variable to identify and
rank genes that are likely to serve as candidate biomarkers. From the Feature Selection
module, a ranking per gene is computed and passed to the Biomarker Size Selection mod-
ule which selects a set number of the top ranked genes for inclusion in the classifier. With
the final set of genes, a classifier is trained in the Classification module on the internal train-
ing set and evaluated on the internal test set. The classifier scores and binary predictions for
each sample in the test set is then written to a file on disk. This process is repeated for all
possible models in cross-validation. By default, the stock pipeline performs leave-group-
out cross-validation for 10 folds with 80% of samples randomly selected for the internal
training set at each fold. A description of each task in each module is provided below.
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Training Set
Gene Filter
Feature Selection
Biomarker Size
Classication
Internal
Training Set
Internal 
Test Set
Figure 3.2: Schematic overview of stock biomarker pipeline. The stock biomarker
pipeline is made up of four modules including gene filter, feature selection, biomarker size,
and classification, with each module containing a number of tasks. A single model in the
pipeline consists of one task from each module. Tasks are evaluated in the order in which
the modules are arranged. When the pipeline is run, the training set is split into internal
trainning and test sets. The tasks for a given model are then evaluated on the internal train-
ing set, resulting in a trained classification model which is evaluated on the internal test
set.
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Table 3.2: Modules and tasks included in the stock pipeline
Module Tasks
gene filter MAD, mean-expression
feature selection SAM, FC + P, t-test, pAUC,
signal-to-noise
biomarker size size selection
classification lda, random forest, naive bayes,
knn, svm, weighted voting, elastic
net
3.2.8.1 Gene Filter Module
The gene filter module contains two tasks: one that filters genes based on median abso-
lute deviation (‘mad’) and a second that filters based on average expression across samples
(‘mean-expression’). The mad task computes the median absolute deviation (MAD; Equa-
tion (3.1)) for each gene, then selects a particular fraction of the genes with the highest
MAD score. Three different values of fraction are evaluated in the stock pipeline (0.25,
0.50, 0.75), effectively converting the mad task into three distinct tasks when the pipeline
is run. The mean-expression task computes the average gene expression across the entire
dataset, then compares the mean expression of each gene to the dataset-mean using a two-
sample Student's t-test. For each hypothesis test, and thus each gene, a p-value is computed
and genes with p-value < 0.05 are selected and retained.
M AD = median( |Xi − median(X ) |) (3.1)
3.2.8.2 Feature Selection Module
The feature selection module contains five tasks including significance analysis of mi-
croarrays (‘SAM’), fold change and p-value (‘FC + P’), Student's t-test (‘t-test’), partial
55
area under the receiver operating characteristic curve (‘pAUC’), and signal-to-noise ratio
(‘signal-to-noise’). The SAM task implements the significant analysis of microarray tech-
nique originally published by Tusher et al. and implemented in the samr R package [104].
Using 100 permutations, p-values are computed from the t-statistics for each gene. Genes
are then ranked by p-value. The FC + P task uses both fold change and p-value to select
and rank genes. First, the association of each gene with the response variable is computed
using a moderated t-test. Next, any gene with a p-value < 0.05 is retained and subsequently
ranked by fold change (Equation (3.2)).
FC =
mean(Xi,y=1)
mean(Xi,y=0)
(3.2)
If no genes pass the p-value threshold of 0.05, all genes are retained and ranked by fold
change. The t-test task computes the association of each gene with the response variable
using a Student's t-test assuming equal variances within each group. Genes are ranked by
p-value. The pAUC task uses the rowpAUCs function in the genefilter R package [36] to
compute the partial area under the receiver operating characteristic curve for each gene.
Gene are then ranked by partial AUC. Finally, the signal-to-noise task computes the signal-
to-noise ratio described by Golub et al. for each gene. Genes are then ranked by this ratio.
3.2.8.3 Biomarker Size Module
The biomarker size module only has one task, ‘size selection’, which selects a certain num-
ber of top-ranked genes based on the rankings produced in the Feature Selection module.
This task evaluates panel sizes of 5, 25, 50, 100, 200, and 500, effectively converting the
size selection task into six unique tasks.
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3.2.8.4 Classification Module
The classification module contains seven tasks including linear discriminant analysis (‘lda’),
random forest (‘random forest’), Naïve Bayes (‘naive bayes’), K-nearest neighbors (‘knn’),
support vector machines (‘svm’), weighted voting (‘weighted voting’), and elastic net
(‘elastic net’). Where possible, the classifiers used within these tasks are implemented
using the caret R package to maintain a uniform interface and syntax. The lda classifier
had no tuning parameters and thus the implementation of its task is straightforward. In the
random forest task, the random forest classifier has tuning parameter mtry for the num-
ber of randomly selected predictors. This parameter is tuned using a random search and
5x repeats of 10-fold cross-validation. The Naïve Bayes task has tuning parameters fl,
userkernel, and adjust, however, by default, no Laplacian correction, bandwidth ad-
justment, or kernel is used to train the classifier. The knn classifier has tuning parameter k
for the number of neighbors to consider when making a classification. Parameter k varies
from one to kmax by two where kmax is the rounded square root of the number of samples
in the internal training set. If kmax is even, a value of one is added to kmax to prevent
ties. The svm classifier has tuning parameter c which is tuned using 5 repeats of 10-fold
cross-validation using a random search. The weighted voting classifier has no tuning pa-
rameters and thus the implementation of its task is straightforward. Finally, the elastic net
classifier has tuning parameters alpha and lambda which are tuned using 5x repeats of
10-fold cross-validation. The search space for parameter alpha is constrained between 0
and 1 while the search space for parameter lambda is between 0.01 and 100.
3.3 Results
In the following section we demonstrate how to analyze a breast cancer microarray dataset
from the MAQC-II study [89] using the stock pipeline. We show how the results from the
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stock pipeline can be used to inform the selection of a final predictive model and how the
performance of the final model on an independent validation set compares to the models
used by data analysis teams in the original study.
3.3.1 Installing the rabbit Package
In its current implementation, the rabbit package is hosted in the Github repository. The
package will be transitioned to Bioconductor upon completion and has been developed
in compliance with Bioconductor contributor standards. However, at the time of writing,
additional features are still being developed and added to the package. These additional
features are beyond the scope of this work but will be briefly discussed throughout the sec-
tions below. The devtools [116] package can be used to install the rabbit package directly
from Github using the install_github function.
R> library(devtools)
R> devtools::install_github("jperezrogers/rabbit", ref="master")
3.3.2 Load the Stock Pipeline
Once the package is installed, the stock pipeline can be loaded using the data function.
A high-level overview of the stock pipeline can be displayed using the summary function
(Figure 3.3). As discussed in the Methods section above, there are 840 unique biomarker
models included in the stock pipeline. By default, the cross-validation scheme is set to
leave-group-out cross-validation with 80% of samples assigned to the internal training set
in each of the 10 iterations. A more detailed summary of the stock pipeline is displayed
using the level=“detailed” argument in the summary function (Figure 3.4). This sum-
mary function shows the breakdown of each of the tasks that will be used when the pipeline
is executed. The total number of models can be calculated by multiplying the number of
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Figure 3.3: Default summary function output. By default, the summary function has
parameter level=“overview” which provides a high-level summary of a pipeline object
including the pipeline’s label, total number of models, cross-validation method, number of
folds, and training set fraction. Depending on the cross-validation method, the number of
folds and training set fraction may or may not be displayed in this summary. For example,
if the cross-validation method is set to ‘cv’ and nfolds set to 10, the training set fraction is
inferred to be to by 90% rather than set by the user and thus not displayed. It is important
to note that the total number of models is based on only those tasks within the pipeline that
are currently active. Inactive tasks do not contribute to the total number of models.
tasks in each module (e.g. 4 gene filter tasks x 5 feature selection tasks x 6 biomarker size
tasks x 7 classification tasks = 840 unique models).
R> library(rabbit)
R> data(stockPipeline)
R> summary(stockPipeline, level="overview")
R> summary(stockPipeline, level="detailed")
3.3.3 Breast Cancer Dataset
To demonstrate the general function and utility of the stock pipeline, we downloaded a
dataset of 230 stage I-III breast cancers obtained via fine needle aspiration and profiled
using Affymetrix Human Genome U133A microarrays (GSE20194) [75]. All samples were
normalized using the MAS5 algorithm. These data were used as part of the MAQC-II
study to evaluate the performance of multiple predictive models developed by a variety of
different groups. Two clinical endpoints were provided for these patients, estrogen-receptor
status (ER+ vs ER-) and response to pre-operative chemotherapy (complete response vs
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Figure 3.4: Detailed summary function output. The summary function will display a
detailed breakdown of the specific tasks within each module if level=“detailed”. The
product of the number of tasks in each module equals the total number of models that will
be evaluated when the pipeline is run. Only tasks that are currently active are displayed in
the output of the summary function.
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Table 3.3: Distribution of ER-positive and ER-negative patients in the training and valida-
tion sets
Training Set
(n=130)
Validation Set
(n=100)
ER+ 80 61
ER- 50 39
residual disease). In the MAQC-II study, the first 130 samples collected were used as a
training set while the latter 100 were used as an independent validation set. The same
training and validation sets are leveraged here with the stock pipeline being run on the
training set and the final model evaluated on the validation set. The distribution of cases
and controls in this cohort are shown in Table 3.3. For the purposes of this example, we
will focus on classifying estrogen-receptor status using the gene expression profiles from
each patient.
R> library(GEOquery)
R> eset <- suppressWarnings(
+ getGEO("GSE20194", GSEMatrix=T)$GSE20194_series_matrix.txt.gz)
R> set <- eset$description
R> training.set.index <- grep(x = set, pattern = "Training")
R> validation.set.index <- grep(x = set, pattern = "Validation")
R> training.set <- eset[ , training.set.index]
R> training.set.y <- as.factor(
+ ifelse(
+ training.set$characteristics_ch1.3 == "er_status: P", 1, 0))
R> validation.set <- eset[ , validation.set.index]
R> validation.set.y <- as.factor(
+ ifelse(
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+ validation.set$characteristics_ch1.3 == "er_status: P", 1, 0))
3.3.4 Running the Stock Pipeline
As discussed above, the stock pipeline contains 840 unique biomarker models which will
each be evaluated on the training set. This collection of models is broad and contains a di-
versity of methods which represent the most commonly employed approaches to biomarker
development as described in the MAQC-II study. Evaluating such a large number of mod-
els is non-trivial and computationally expensive. Efforts have been made within the rabbit
package to optimize the efficiency of evaluating these models, however, depending on the
cross-validation scheme and model composition, the pipeline can take on the order of tens
of hours to complete. The default strategy for evaluating these models is to serially per-
form cross-validation where the performance of each model in the first iteration of cross-
validation is computed, followed by the second iteration and so on. A second strategy is
to run each iteration of cross-validation in parallel across a number of machines on a high-
performance compute cluster such as a Sun Grid Engine. This dramatically reduces the
total amount of time required to complete a run of the stock pipeline and enables more
rapid model development and evaluation. Each of these strategies are discussed in more
detail below. In either scenario, the prediction scores, binary classifications, and genes
used in the classifier are written to the file system for each model in each iteration of cross-
validation. The breast cancer dataset is evaluated using both of these techniques below.
3.3.4.1 Evaluation in Series
Running the stock pipeline in series is straight forward using the run command. The
function takes in the training set gene expression matrix x and the response variable y.
The output directory defaults to the current working directory and the seed is set for repro-
62
ducibility. Using the default cross-validation configuration, the training dataset is randomly
split into internal training and test sets. The first cross-validation loop is initiated and each
of the 840 models are evaluated on the internal training set. Once the classifier within each
model has been built, its performance on the internal test set is computed and written to
a file. This process is repeated for each cross-validation iteration until all iterations have
been run. Setting verbose equal to true in the run function will provide the user with helpful
messages that can be used to monitor the progress of the pipeline run.
R> run(stockPipeline, x = exprs(training.set), y = training.set.y,
+ seed = 1234, verbose = TRUE, force = TRUE)
3.3.4.2 Evaluation in Parallel
Evaluation of the stock pipeline in parallel accomplishes the same goal as running it in
series with the added benefit of dramatically reducing total computational time. The run
function is designed to allow the user to run only a single iteration of cross-validation at
a time instead of the entire process. This is accomplished by setting the iter argument
to an integer value between one and the total number of folds. Using this methodology,
each iteration of cross-validation can be run on a separate machine at the same time and
the results merged after all processes have completed.
R> run(stockPipeline, x = exprs(training.set), y = training.set.y,
+ seed = 1234, verbose = TRUE, force = TRUE, iter = 1)
There are a number of different strategies for implementing this parallel processing
procedure. For the purposes of this example, we demonstrate parallel processing of the
stock pipeline using a Sun Grid Engine compute cluster with a qsub job-submission system.
Briefly, a bash shell script (Appendix G) is used to submit each cross-validation loop to
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the cluster as a separate job. The shell script calls a qsub script (line 15) and passes it the
cross-validation iteration number to run using the variable i. The qsub script (Appendix H)
contains all of the instructions for running the given cross-validation iteration on the cluster
using R. This script runs an R script which loads the training dataset, rabbit library, and the
stock pipeline and then runs the pipeline using the iteration number passed through the
shell script and qsub script. Each of the jobs will write results to the output directory in the
folders that correspond to the given cross-validation iteration. It is important to note that
the seed is set to 1234 each time the run function is called. This is a critical input parameter
when running the pipeline in parallel as it ensures that each instance of the pipeline is using
the same split of samples for cross-validation. If the seed argument is not set the results
from cross-validation will be invalid and uninterpretable.
3.3.5 Interpreting Pipeline Output
3.3.5.1 Directory Structure
The stock pipeline writes the results of each model within each iteration of cross-validation
to the file system using a hierarchical directory structure. In our example using the breast
cancer dataset, ten directories were created in the output directory, one for each of the cross-
validation iterations. Within each cross-validation loop directory are 840 sub-directories
each storing the results from one model. Within each model directory are two files, one
which contains the classifier scores and binary classifications for the internal test set sam-
ples, and a second file which contains the gene names for the genes included in the classi-
fier.
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3.3.5.2 Summarization
The overall performance of each model is assessed by summarizing the results across
all cross-validation iterations. The summarization strategy is dependent upon the cross-
validation scheme that was employed. For leave-group-out cross-validation, as in our ex-
ample, the AUC and MCC are computed for each model within each cross-validation itera-
tion. These values are then averaged across all iterations to yield a single value representing
the ‘average’ performance of the model in cross-validation. The AUC value is a function of
the classifier scores and is computed using the pROC R package [80]. MCC is dependent
upon the binary classifications predicted by each classifier and is computed using equation
Equation (3.3). A snapshot of the models with the highest AUC and MCC when predicting
ER-status in our breast cancer dataset are shown in Table 3.4 and Table 3.5, respectively.
The genes used for each model across cross-validation iterations can also be summarized
in a model-wise or global manner. Figure 3.5 shows the 50 most selected genes in cross-
validation for the best performing model by AUC while Figure 3.5 shows the distribution
of the 50 most selected genes across all models in our breast cancer dataset.
MCC =
(T P ∗ T N ) − (FP ∗ FN )√
(T P + FP) ∗ (T P + FN ) ∗ (T N + FP) ∗ (T N + FN ) (3.3)
3.3.5.3 Picking a Final Model
There are a number of different methods that can be employed to select a final model
from the results of a pipeline run. Rather than simply selecting the model that achieves
the best performance in cross-validation, our strategy is to examine model performance
as a function of the tasks within each module and to select the tasks that yield the best
average performance. By examining overall model performance as a function of the tasks
that make up each model, we can gain insight into which tasks have the biggest impact
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Figure 3.5: 50 most selected genes in cross-validation for model 142. Model 142 used
median absolute deviation with a fraction size of 25% for gene filtering, partial AUC for
feature selection, a panel size of 50 genes, and a random forest classifier. 27 genes were
selected for inclusion in the biomarker in all 10-folds of cross-validation with another 6
genes selected in 9 out of 10 iterations.
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Figure 3.6: 50 most selected genes in cross-validation across all models. The top 50
genes selected in cross-validation for each model were identified resulting in 840 lists of 50
genes each which were then pooled together. The frequency of each gene is displayed in
the barplot above. No gene was included in the final panel in all models. Gene 202089_at
was selected for inclusion in the final classification model in >600 out of 840 biomarker
models. Only 6 genes were included in >50% of models while 29 genes were included in
>33% of models.
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on model performance. Figure 3.7 shows the distribution of model AUCs in our example
dataset as a function of the tasks within each module. From this plot, it is apparent that all
MAD tasks within the gene filter module had approximately the same median AUC with
the interquartile range (IQR) increasing slightly as the fraction of genes retained by the task
increased from 25% to 75%. The mean-expression gene filter task had approximately the
same IQR as the MAD filter selecting 25% of genes, however the median AUC value was
slightly lower for this task (Figure 3.7, part A). As a result, we selected the MAD task with
fraction equal to 0.25 as our final gene filter method.
The partial AUC, signal-to-noise ratio, and t-test feature selection tasks had very simi-
lar overall performance (Figure 3.7, part B). Similar to the gene filter selection procedure,
deciding among these three tasks will likely not impact the final model dramatically. How-
ever, given that the partial AUC task demonstrated the highest median AUC and smallest
IQR, it could reasonably be selected as the feature selection task for the final model. It is
important to note that while many tasks in a given module may be included in models that
achieve approximately the same performance in cross-validation, there are certain tasks,
such as the fold change + p-value task in our breast cancer dataset, which have a significant
positive or negative impact on the performance of the models they're included in. The se-
lection or avoidance of these tasks depending on their impact on the performance of models
is a critical piece of information that can be gained from the results of a pipeline run.
The median AUC of models as a function of the biomarker panel size was similar for
biomarkers made up of 5, 25, and 500 genes (Figure 3.7, part C). The IQR was twice as
large in the negative direction with the 5-gene task vs the 25-gene task. Given the tighter
IQR and simpler model that would result from the 25-gene task vs the 5-gene or 500-gene
task, respectively, the 25-gene size selection task was chosen for the final model. Finally,
the elastic net classifier showed the highest median AUC and smallest IQR and was chosen
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Figure 3.7: Stock pipeline model performance by AUC on breast cancer dataset. A)
Model AUC as a function of gene filter task. B) Model AUC as a function of feature
selection task. C) Model AUC as a function of biomarker panel size. D) Model AUC as a
function of classifier.
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Figure 3.8: Stock pipeline model performance by MCC on breast cancer dataset. A)
Model MCC as a function of gene filter task. B) Model MCC as a function of feature
selection task. C) Model MCC as a function of biomarker panel size. D) Model MCC as a
function of classifier.
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as the classifier for the final model (Figure 3.7, part D). An alternative strategy would be
to select parameters based on MCC rather than AUC (Figure 3.8). However, given that
the classifiers in the stock pipeline have been designed to tune hyperparameters based on
AUC, we have chosen to remain consistent and select our final model using AUC rather
than MCC.
3.3.6 Training and Evaluating the Final Model
Once the parameters of the final model have been chosen, the trainFinalModel function
can be used to build the final predictive model on the entire training set. In our example,
the 100 samples that were used as a validation set in the MAQC-II study were also used as
a validation set in this study. In this cohort, the elastic net classifier selected above achieved
an AUC of 0.92 (Figure 3.9) and MCC of 0.79. Compared to the data analysis teams that
participated in the MAQC-II study, our model would have placed first in the breast cancer
dataset challenge with the highest MCC score and an improvement of 0.004 over the next
best team.
3.4 Conclusions
The computational development of biomarkers from high-dimensional genomic data is a
complicated multi-step process that needs to be tailored to each unique dataset. With a
nearly countless number of methods available for normalization, batch correction, gene
filtering, feature selection, and classification, as well as a number of cross-validation and
hyper-parameter tuning techniques, it can be challenging to identify the best combination of
methods to use without having extensive previous experience with biomarker development.
Here, we have presented a solution to this problem in the form of an R-package which pro-
vides users with access to a stock computational pipeline to systematically evaluate the
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Figure 3.9: Performance of the final elastic net classification model. The final model,
which used median absolute deviation with a fraction size of 25% for gene filtering, par-
tial AUC for feature selection, a biomarker panel size of 25, and an elastic net classifier,
achieved an AUC of 0.92 in the 100 sample independent validation set.
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performance of 840 unique biomarker development models including various methods for
gene filtering, feature selection, biomarker panel size, and classification. The stock pipeline
is accessible through simple and intuitive functions and can be executed with a single com-
mand. The 840 models included in the pipeline were selected to cover the broad diversity
of available methods commonly used within the community and provide users with access
to pre-implemented techniques that may be outside of their typical toolkit. Also available
within the package are a number of utility functions for customizing existing pipelines or
building entirely new biomarker discovery pipelines from scratch. These functions provide
users with a structured framework to which they can add their own modules and tasks to
truly tailor the model development process to a given dataset.
We demonstrate the effectiveness of our R-package using real world breast cancer mi-
croarray data from the MAQC-II study. We used the stock pipeline to evaluate the perfor-
mance of 840 models in predicting estrogen receptor status in a training set of 130 patients.
Based on the results from the pipeline we selected a final model which filtered genes using
median absolute deviation, ranked genes by their partial AUC, selected a final panel size of
25 genes, and trained an elastic net classifier on the training set. We evaluated this model
in an independent set of 100 samples and showed that the model achieved an AUC of 0.92
and an MCC of 0.79 which would have placed first among the data analysis teams in the
MAQC-II challenge, highlighting the strength of this approach. The rabbit R-package is
freely available and provides the community with a novel and powerful tool for biomarker
development using high-dimensional microarray data.
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Chapter 4
GENERAL CONCLUSION
This work establishes, for the first time, that the lung cancer-associated airway field of
injury observed in bronchial epithelium extends to the nasal epithelium and that nasal ep-
ithelial gene expression can serve as a non-invasive molecular biomarker of lung cancer.
Furthermore, this work has shown that nasal gene expression provides unique information
about the presence of lung cancer that is not captured by clinical covariates and that by
adding gene expression to these covariates, we can significantly improve the AUC, sen-
sitivity, and negative predictive value of the predictions compared to the clinical model
alone. The establishment of a cancer-associated field of injury in nasal epithelium sets the
stage for the development and refinement of nasal gene expression biomarkers that can be
used by physicians to help manage patients with indeterminate pulmonary nodules. Fur-
thermore, in patients with contraindications to bronchoscopy, a nasal gene expression test
for lung cancer could serve as an alternative diagnostic modality. This work represents the
first milestone in the development of nasal gene expression-based clinical tests for lung
cancer. It will now be of interest to the community to develop similar tests for patients in
the lung cancer screening setting where the frequency of nodules and nodule size tends to
be smaller. A nasal biomarker with efficacy in this setting has the potential to dramatically
improve the throughput of lung cancer screening programs by identifying patients at the
highest risk of lung cancer and by minimizing invasive follow up procedures in patients
with benign lung nodules.
The computational methodology used to develop the nasal biomarker presented here
is the culmination of years of experience and work on behalf of a team of computational
biologists. While this methodology was developed in our lab based on the findings from
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the MAQC-II study, others have independently developed similar approaches which have
been shown to perform exceptionally well in identifying optimal biomarkers across diverse
datasets. None of these implementations, however, are portable or designed for massive
consumption by the community. Here, we presented a formalization of our methodology
and have developed a freely available open-source R-package designed to be accessible to
the broad community of computational biologists and researchers. The R-package provides
users with access to hundreds of pre-built biomarker development models which can be ex-
ecuted using intuitive interfacing functions. Also provided are utility functions that allow
for customization, expansion, and development. It is our hope that this R-package will pro-
vide the broad research community with access to powerful modeling tools and techniques
and will result in the development of robust biomarkers to diagnose disease.
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Appendix A
CLINICAL PATHOSCOPE: RAPID ALIGNMENT AND FILTRATION FOR
ACCURATE PATHOGEN IDENTIFICATION IN UNASSEMBLED
SEQUENCING DATA
A.1 Abstract
The use of sequencing technologies to investigate the microbiome of a sample can pos-
itively impact patient healthcare by providing therapeutic targets for personalized disease
treatment. However, these samples contain genomic sequences from various sources that
complicate the identification of pathogens.
Here we present Clinical PathoScope, a pipeline to rapidly and accurately remove host
contamination, isolate microbial reads, and identify potential disease-causing pathogens.
We have accomplished three essential tasks in the development of Clinical PathoScope.
First, we developed an optimized framework for pathogen identification using a computa-
tional subtraction methodology in concordance with read trimming and ambiguous read re-
assignment. Second, we have demonstrated the ability of our approach to identify multiple
pathogens in a single clinical sample, accurately identify pathogens at the subspecies level,
and determine the nearest phylogenetic neighbor of novel or highly mutated pathogens us-
ing real clinical sequencing data. Finally, we have shown that Clinical PathoScope outper-
forms previously published pathogen identification methods with regard to computational
speed, sensitivity, and specificity.
Clinical PathoScope is the only pathogen identification method currently available that
can identify multiple pathogens from mixed samples and distinguish between very closely
related species with very little coverage of the genome. Furthermore, Clinical PathoScope
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does not rely on genome assembly and thus can more rapidly complete the analysis of
a clinical sample when compared with current assembly-based methods. Clinical Patho-
Scope is freely available at: http://sourceforge.net/projects/pathoscope/.
A.2 Introduction
Despite recent advances in diagnostic and preventative medicine, infectious diseases still
account for a large proportion of the disease burden and mortality worldwide, particularly
in low-income areas and developing countries [66]. Current clinical diagnostic tests for
identifying infection-causing pathogens utilize limited technologies such as polymerase
chain reactions (PCR), Sanger sequencing, or cell culture. These methods typically focus
on identifying only a single pathogen at a time and often lack the specificity required to
distinguish between closely related species or strains of the same species. Bacterial cultures
can accurately identify culturable pathogens, but usually require 4-5 days to complete and
cannot be conducted for all pathogens [28]. Microarray technologies, such as the Virochip
[18], have been shown to be useful in the space of pathogen identification. Microarrays,
such as these, are designed to detect both known and novel pathogens through the use of
high-sensitivity probes and probes that map to conserved genomic regions. While useful
for broad spectrum screening of clinical samples, this technology is limited in that probes
must be continually designed and updated to support the ever growing number of genomic
sequences in public databases.
In recent years, researchers have taken advantage of innovations in sequencing tech-
nologies to more rapidly identify and characterize pathogens responsible for disease out-
breaks, including the West Nile Virus [56], H1N1 influenza [55, 40, 26], cholera [23],
Escherichia coli [35, 82, 108, 78], Salmonella [62], and antibiotic resistant Klebsiella pneu-
monia [93]. Traditionally, sequencing a single sample has taken as long as several days or
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weeks using the most common platforms. Recent commercial efforts, however, have re-
duced this time to a few hours or days [84]. Within the next few years, newer technologies
are promising sequencing runs in less than an hour with a cost of under one hundred dol-
lars [84]. Once these technologies become widely accessible, the use of sequencing as a
diagnostic tool in the clinic will have great potential for more personalized medical ap-
plications. The rapid and accurate analysis of next-generation sequencing data, however,
remains a challenge for many reasons. The sheer volume of data, for example, is difficult
to deal with computationally without significant computational resources (e.g., a typical
sequencing run on the Illumina HiSeq 2500 can yield 300M million reads requiring 30
GB of storage capacity and significant RAM requirements for processing). Furthermore,
DNA from host genomes or commensal species will often dominate clinical samples and
sequencing error can swamp out diagnostic signal. These challenges highlight the need for
the development of highly sensitive algorithms that can distinguish among closely related
pathogenic strains in a computationally efficient manner.
Current sequencing-based diagnostic methods [53, 70, 8, 88, 45, 74, 13] require thou-
sands of reads from the pathogen and include computationally intensive steps such as
genome assembly, multiple genome alignments, extensive homology searches, and/or phy-
logeny estimation, with some methods taking upwards of three days to complete a single
run [53]. Additionally, these methods fail to accurately identify pathogens at the strain level
and will often assign ambiguously aligned reads to higher taxonomic levels which may lead
to a nonspecific or incorrect diagnosis and the administration of ineffective clinical treat-
ments. Such was the case during the European outbreak of hemorrhagic Escherichia coli,
which resulted in 3,800 infections and 54 deaths across 13 countries due to a 3-week delay
in appropriate intervention [35]. The challenges encountered when diagnosing viral and
bacterial pathogens in the clinic reinforce the need for a streamlined sequencing protocol
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and a highly sensitive computational method by which strain specific identification can be
rapidly achieved. By helping clinicians to direct treatment and avoid misdiagnoses, the
identification of viral and bacterial pathogens in clinical samples will directly benefit pa-
tients suffering from a variety of infectious diseases [9]. In particular, assigning a viral
rather than bacterial cause to an infection may help alleviate the antibiotic overuse that is
common in clinical practice today [119]. Recent editorials and reviews express concern that
analysis, rather than data generation, is likely to be the limiting factor for sequence-based
clinical pathology; thus, clearly highlighting the need for ‘clinic-ready’ software tools and
approaches [28, 111, 14, 105, 31].
Here we present Clinical PathoScope, a rapid alignment and filtration pipeline for accu-
rate viral and bacterial pathogen identification using unassembled sequencing data. Using
a variety of clinical samples and simulated scenarios, we demonstrate our method’s ability
to differentiate between pathogens, identify multiple pathogens in a single clinical sample,
and identify the closest relative to highly mutated and novel strains. Clinical PathoScope
builds on the previous success of PathoScope v1.0 [34], which capitalizes on a Bayesian
statistical framework to process an alignment file and provide posterior probability pro-
files of organisms present. While PathoScope v1.0 showed success when used with puri-
fied samples, it was necessary to develop a method to remove potential contaminating se-
quences from the host and commensal microbes for host-dominated clinical samples. Clini-
cal PathoScope incorporates the original PathoScope algorithm into a novel pipeline that al-
lows users to go directly from metagenomic sequencing reads to a list of organisms present
in a sample in one easy step and in a clinically relevant timeframe. For convenience, we
provide bacterial and viral databases curated from NCBI; however, custom databases can
easily be incorporated as well. Taken together, these features make Clinical PathoScope the
fastest and most accurate pipeline currently in the literature for identifying strain-specific
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pathogens in clinical samples without the need for genome assembly. Clinical PathoScope
(version 1.0) is freely available at: http://sourceforge.net/projects/pathoscope/.
A.3 Methods
In order to develop the Clinical PathoScope framework, we have accomplished the fol-
lowing essential tasks for pathogen identification in clinical samples: 1) selection of the
most appropriate alignment algorithm and parameters for optimal performance on clinical
samples, 2) evaluation of filtering approaches to efficiently remove reads from a clinical
sample that originated from host, non-target, or non-pathogenic genomes, and 3) the evalu-
ation and comparison of Clinical PathoScope with existing approaches using multiple real
datasets (see Figure A.1 for Clinical PathoScope development workflow). Details regard-
ing the specific methods evaluated, pipeline modules, and results observed are given in the
subsequent sections. Finally, we have implemented these results into a highly sensitive
and efficient pipeline that is user-friendly and approachable by physicians and researchers
without the requirement of advanced computational expertise.
A.3.1 Clinical PathoScope Pipeline Development and Evaluation
The Clinical PathoScope pipeline consists of three primary steps: 1) optimized read align-
ment, 2) host and non-target genome filtration, and 3) ambiguous read reassignment. We
developed the optimized Clinical PathoScope algorithm using a set of simulated clinical
samples (described below) and later validated our method and compared our results against
existing approaches using multiple clinical datasets, some of which are original to this
publication.
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Figure A.1: Workflow employed to develop the Clinical PathoScope pipeline. Three
reference genome libraries were downloaded from NCBI. Four alignment algorithms were
tested and evaluated on five simulated clinical sequencing samples. Each aligner was pa-
rameter tuned and optimized and Bowtie2 was selected as the choice aligner for the Clinical
PathoScope pipeline. The order with which reads are aligned to the reference libraries was
determined and the performance of Clinical PathoScope was evaluated using four clinical
datasets. Furthermore, we compared our results against those produced by existing tech-
nologies.
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A.3.1.1 Reference Genome Library Curation and Processing
One of the most important steps for the accurate identification of benign and pathogenic
genomes is to build a comprehensive genome library containing all species and strains
likely to be present in the sample. This is a critical step as Clinical PathoScope can only
identify organisms or their nearest neighbors if they are present in the library. In order
to maximize the characterization of all reads within a given clinical sample, our method
aligns reads against three broad categories of reference genomes. The human host library
consisted of two sequences totaling 3.2 gigabase-pairs (Gbps); the GRCh37/hg19 build of
the human genome, as well as the human ribosomal DNA sequence (GenBank:U13369).
The ribosomal reference was included in order to remove several false positive alignments
to viral genomes that share sequence similarity with human ribosomal RNA (a list of these
viral genomes is available online (Additional file 2)). The bacterial library was downloaded
from NCBI (ftp://ftp.ncbi.nlm.nih.gov/genomes/Bacteria/all.fna.tar.gz, 12/15/12) and con-
tained 2,402 complete reference genomes and 1,759 plasmid sequences. In all, this bac-
terial library consisted of 7.7 Gbps of DNA sequence. Due to restrictions enforced by
some of the aligners with regard to index size, it was necessary to split this library into
two smaller segments to facilitate proper alignment. Finally, the viral library was also ob-
tained from NCBI (ftp://ftp.ncbi.nlm.nih.gov/genomes/Viruses/all.fna.tar.gz, 1/10/13). For
genomes in which multiple segments were available, all segments for a given genome were
concatenated into a single contiguous sequence with each segment separated by a series of
null characters (N's). In total, the viral library contained 3,738 complete genomes and 110
megabase-pairs (Mbps) of total sequence.
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A.3.1.2 Generation of Simulation Study Datasets
We simulated two sets of five in silico clinical samples to represent a variety of clinical
scenarios including infections with two or more disease causing and benign pathogens, in-
fections with a pathogen having closely related substrains (e.g. Human adenovirus), and
infections with highly mutated pathogens. The first set of simulated samples was used
to evaluate several alignment algorithms and to optimize the architecture of the Clinical
PathoScope pipeline. The second set was then used to evaluate the efficacy of Clinical
PathoScope alongside existing technologies. Importance was placed on implementing ac-
curate mutation rates, genome diversity, and relative compositions. Functioning as positive
controls, these data were essential to develop a robust pipeline for pathogen identification.
Each sample was composed of human, bacterial, and viral sequences mimicking the mi-
crobiota found in sequencing data from nasopharyngeal samples during a respiratory tract
infection [121, 11]. Specifically, 10 million 100-base reads were generated for each sample
with 90% of reads originating from the host transcriptome (human RNA), 9% from bac-
terial genomes, and 1% from viral genomes. The first set of simulated samples contained
sequencing reads from five bacterial and six viral genomes at various depths of coverage.
This was essential to determine how each aligner and pipeline architecture performed with
respect to the number of reads originating from each genome. The second set of simulated
samples were designed as a more challenging and realistic dataset and was used to evaluate
our optimized approach. Each sample contained sequences from six viral genomes and
twenty-five bacterial genomes. The number of reads originating from each viral genome
ranged from ten to 63,640. To determine a realistic bacterial landscape for these samples,
we downloaded and aligned three anterior nares samples (SRA: SRS011105, SRS012291,
SRS013637) from the Human Microbiome Project (http://hmpdacc.org/HMASM/) and se-
lected 25 of the most common bacterial strains (19 unique species) to be included in our
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simulation. The number of reads originating from each bacterial genome was determined
by sampling a Gaussian distribution such that the number of bacterial reads per sample
totaled 900,000. Reference genomes for each of the representative species were obtained
from NCBI's RefSeq database [77] and samples were simulated using the next-generation
read simulator, Mason [42], employing its ‘Illumina sequencing’ error-model. Previously
published species or kingdom specific mutation rates for SNPs and indels were applied to
the human [1], bacterial [22], and viral [85] genomes to accurately capture the variabil-
ity inherent in clinical samples. The simulated datasets are available for download on the
PathoScope software distribution site and will be useful for benchmarking and comparing
future metagenomic analysis pipelines. The specific parameters and code used to generate
this dataset as well as accession numbers of reference genomes and actual read proportions
of each genome within each sample are available online (Additional file 3).
A.3.1.3 Alignment Optimization
We evaluated and compared four publicly available alignment algorithms (Bowtie2.0.0
[57], BWA 0.6.2 [60], PBLAT 2.0.0 [51], SOAP2 2.21 [61]) based on three criteria, namely,
1) run time, 2) sensitivity and 3) specificity by aligning our first set of five simulated sam-
ples against the human, bacterial, and viral reference libraries described above (see Fig-
ure A.2 for aligner evaluation schematic). Run time was measured as cpu minutes using
8 cores and a single 2.3 GHz AMD Opteron processor on the Boston University Medical
Campus LinGA cluster. Using the resulting alignment files and the known origin of the
reads, sensitivity was measured as the number of true positives divided by the number of
true positives plus false negatives, and specificity was measured as the number of true neg-
atives divided by the number of true negatives plus false positives. Our goal was to identify
the algorithm and parameters that provided the best balance of our three evaluation criteria.
86
Bowtie 2 
SOAP 2 
BWA 
PBLAT 
Δ 
Parameters 
25 
50 
75 
100 
Human 
Bacterial 
Viral 
Evaluation 
Aligner Read Length Library 
Figure A.2: Alignment optimization variables and methods. The internal parameters
for each of the four aligners were varied and tuned. Additionally, the length of each read
aligned was varied. For each unique aligner-parameter-read length configuration, the sen-
sitivity, specificity, and run time when aligning the simulated samples against the reference
genome libraries was calculated.
Additionally, we examined the effect of varying the length of each read on the number of
reads correctly aligned to the reference genomes using the first 25, 50, 75, and 100 base-
pairs, as well as the full-length sequence. Evaluating variable read lengths served multiple
purposes: 1) determining whether aligning the entire read was necessary, or if aligning a
smaller segment of the read performed just as well, 2) identifying optimal sequence read
size for future studies, and 3) evaluating whether aligning a smaller portion of the read
can replace the need for a computationally intensive spliced-read alignment algorithm for
reads from host/filter genomes that contain spliced gene transcripts. The version informa-
tion, run commands, and alignment results for each algorithm and all parameters evaluated
are available online (Additional files 5 and 6).
A.3.1.4 Filtration Optimization
We employed a computational subtraction methodology [120] in which reads are sequen-
tially aligned against a series of reference genomes to determine their origin. For our
purposes, we aligned reads against libraries of reference genomes originating from human,
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bacteria, or viruses. Within our pipeline, reads that align to the target library (e.g. viral li-
brary for virus detection) are retained while reads that align to the host (e.g. human library)
and non-target (e.g. bacterial library) sequences are removed. The effects of varying the
order of subtraction were examined by comparing the resulting alignment sensitivity, speci-
ficity, and pipeline run time using all six permutations of our three libraries. Additionally,
we evaluated the effect of using the PathoScope expectation maximization (EM) algorithm
[34] to minimize false positive mappings by reassigning reads with ambiguous alignments
to their correct genome of origin. A detailed diagram of the overall experimental design is
shown in Figure A.1. The subtraction methods evaluated for use in our pipeline as well as
the optimal method are shown in Figure A.3.
A.3.2 Clinical Datasets
A.3.2.1 Prostate Cancer Cell Line (PCCL)
The PCCL dataset [76] has been leveraged in previous studies as a positive control and a
means for comparing algorithm run time. This dataset is derived from a prostate cancer
cell line infected with the human papillomavirus serotype 18. The RNA sequencing was
performed using an Illumina GA II sequencer and 26,958,682 reads (40 bases each) were
publically available (SRA:SRR073726).
A.3.2.2 New World Titi Monkey Adenovirus Outbreak (TMAdv)
Sequencing reads from two New World titi monkeys (Callicebus cupreus) infected with a
highly divergent adenovirus [19] make up the third dataset used to evaluate Clinical Patho-
Scope. The samples originated from an outbreak of an unknown virus in a colony of titi
monkeys in California. Tissue samples were obtained from the lungs of two titi monkeys
during necropsy and were sequenced together using the Illumina GA IIx for 73 cycles in
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Figure A.3: Subtraction and filtration optimization methods. Various filtration meth-
ods were tested in an effort to minimize computational burden and maximize accuracy.
Approaches tested include A) Naïve Approach, B) Target Centric, C) Target Centric + Re-
assignment, D) Host Centric + Reassignment, and E) Host Centric. Post filtration, all reads
are aligned against the target genome library. The resulting read alignments are reassigned
to the correct genome of origin using the PathoScope Expectation Maximization algorithm.
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both directions yielding 12,393,506 reads (73 bases). Chen et al. identified the cause to be a
new highly divergent species of adenovirus that was subsequently assembled and so named
Titi Monkey adenovirus (TMAdv). We supplemented our host library with the most closely
related, fully sequenced simian species, Callithrix jacchus (GenBank:PRJNA46205). As
a positive control, we included the TMAdv genome in our target library and validated
that Clinical PathoScope accurately distinguished the TMAdv from all other adenovirus
genomes.
A.3.2.3 Tuberculosis in a Mummy
Sequencing reads from a 200 year old mummy infected with tuberculosis were obtained
from a previous study [15] and used to evaluate Clinical PathoScope's ability to detect
bacterial pathogens. The sample was collected from lung tissue taken from the left side
of the thorax of a mummified body. Pulmonary tuberculosis was suspected because of the
cathectic state of the body and confirmed based on PCR analyses. As further validation, the
sample was sequenced on the Illumina Miseq instrument for 300 cycles in both directions
yielding 5,541,400 reads with an average length of 297 basepairs; the reads were retrieved
from Sequence Read Archive with accession number SRP018736. For analysis with Clin-
ical PathoScope, the reads were split into 12,261,862 reads of approximately 100 bases in
length.
A.3.2.4 16S Amplimer Sequencing (16S)
In addition to testing our approach on in silico and previously published clinical datasets,
we validated our approach on data from our own clinical samples. Under an IRB-approved
protocol, deep endobronchial aspirates from 3 patients intubated for mechanical ventila-
tion were obtained after the aspirate had been used for microbiologic testing directed by
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their medical team. The bacteriological staining of aspirate samples revealed the presence
of Gram-negative bacteria, and bacterial culture from aspirates identified abundant Pseu-
domonas (patients F1 and G1) and Enterobacter (patient H1), with opportunistic flora in
all samples. All three patients were on antibiotic treatment regimen prior to the collec-
tion of samples. Patient F1 was treated with a combination of aminoglycoside (gentamicin
and tobramycin) and polymyxin (colistin) antibiotics; patient G1 was on gentamicin/to-
bramycin regimen only, and patient H1 was treated with third generation cephalosporin an-
tibiotics (ceftazidime). In addition to clinical samples, we collected the bacterial DNA from
gram-positive and gram-negative ATCC reference strains: Staphylococcus aureus (ATCC
No. 25923 - MSSA), Enterococcus faecalis (ATCC No. 51299), Pseudomonas aeruginosa
(ATCC No. 27853), Escherichia coli (ATCC No. 25922). Total DNA from these samples
was isolated by centrifugation, and solubilization of the pellet using the Sigma GeneElute
kit combined with a lysis buffer by mixing together the Gram+ and Gram- buffers supple-
mented with lysozyme (2.115X10 6 units/mL), lysostaphin (200 units/mL), mutanolysin
(5000 units/mL). Nanodrop and Qubit measurement of concentrations were used to quan-
tify DNA. After DNA isolation, we amplified the 16S rRNA using the U1492R, Tm 49.44
(GGTTACCTTGTTACGACTT) and B27F, Tm 41.67 (AGAGTTTGATCCTGGCTCAG)
universal primers using 800 ng of template. The amplimers were ligated into SMRTbells
and sequenced on a Pacific Biosystems RS. The sequencing yielded an average of 4,127
reads per sample, averaging 1,178 bases long. For analysis with Clinical PathoScope, the
PacBio reads from each sample were split into 100 base segments that were then treated
as individual reads, generating on average 39,183 reads of 100 bases per sample. To ac-
commodate the high homologies of 16S RNA sequences from different bacterial species
and strains, the alignment parameters for this dataset were tightened compared to the viral
samples, allowing 1 mismatch per 100 bases during alignment, and allowing for multiple
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‘best’ hits per read (e.g. Bowtie2 ‘k’ set at 1,000). These data were submitted to the NCBI
Sequence Read Archive (SRA) database under accession number SRP028704.
A.3.3 16S Phylogenetic Inference
We took all genomes from GenBank's RefSeq database belonging to Pseudomonas, En-
terobacter, and Acinetobacter genera (56 taxa) and generated a BLAST database, which
we queried with a full-length 16S rDNA sequence [4]. We selected one copy per species
and aligned the resulting dataset using a secondary structure aware algorithm (Q-INS-i)
as implemented in MAFFT [49]. We ran 10 independent Maximum Likelihood searches
in RAxML [96] (1000 bootstraps) assuming a GTR nucleotide substitution model with
gamma distributed rate heterogeneity. Additionally, we obtained diagnostic characters
defining particular species using the phylogeny-aware algorithm implemented in CAOS
[86].
A.3.4 Clinical Dataset Preprocessing
The four clinical datasets were used to evaluate our Clinical PathoScope pipeline and to
compare our method against previously published algorithms. A summary of these datasets
is available online (Additional file 8). Extensive quality control was performed uniformly
on each of the datasets to remove low quality and artificial sequences using PrinSeq [87]
(-derep 123; -lc_method dust; -lc_threshold 40) and Cutadapt [65], respectively. For
each read, bases having a Phred quality score less than 20 were trimmed from the 3’ end
and reads with a median quality score below 20 were removed. Low complexity and re-
dundant reads were determined using PrinSeq and removed along with adapter and primer
sequences (see Additional file 9 online for a complete list of adapter and primer sequences).
A minimum read length of 25 base pairs was strictly enforced for trimmed reads to facil-
92
itate accurate sequence alignment. Reads that failed to meet the length requirement were
not considered for further analysis.
A.3.5 Comparison to Published Algorithms
Clinical PathoScope was evaluated alongside two existing pathogen identification algo-
rithms, RINS [8] and READSCAN [70] to emphasize the major differences in performance
between assembly-based approaches and our implementation of computational subtraction
with varying read length and ambiguous read reassignment. All three methods were com-
pared based on their ability to rapidly identify the pathogens present in the clinical datasets
described above. We also considered several published metagenomic-like pipelines such
as CloVR-Metagenomics [6], IMSA [29], LMAT [5], and metAMOS [106] in the context
of pathogen identification.
A.4 Results
A.4.1 Comparison of Alignment Algorithms
The internal parameters for each alignment algorithm were evaluated and tuned to maxi-
mize alignment sensitivity and specificity as well as to minimize run time by mapping reads
from our first set of simulated samples to the reference libraries (see Additional files 5 and
6 online). The average alignment results and confidence intervals of each algorithm using
optimized parameters and read lengths are shown in Table A.1. When aligning reads to the
human library, SOAP2 was on average 30.5% faster than Bowtie2; however, Bowtie2 had a
15.0% higher average sensitivity at 90.2% and a more consistent run time. For alignments
to the viral library, PBLAT had the highest average sensitivity of 99.8%. Bowtie2 also
achieved a high average sensitivity of 98.1% with an 80% reduction in average runtime
compared with PBLAT. For alignments to the bacterial library, PBLAT had the highest av-
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erage sensitivity of 98.9%; however, it took almost 20 times longer than Bowtie2, which
had an average sensitivity of 79.8%. Overall, Bowtie2 offered the best combination of sen-
sitivity, specificity, and speed when aligning reads against the human, bacterial, and viral
libraries.
Table A.1: Simulation study alignment statistics using optimal model parameters
Human Virus Bacteria
Sensitivity Sensitivity SensitivityTime (m)
Specificity
Time (m)
Specificity
Time (m)
Specificity
90.2 ± 0.0 98.1 ± 0.6 79.8 ± 0.1Bowtie2 8.2 ± 0.0
100.0 ± 0.0 3.3 ± 0.6 99.8 ± 0.2 15.8 ± 1.6 100.0 ± 0.0
89.9 ± 0.0 76.8 ± 0.6 —BWA 22.8 ± 3.2
100.0 ± 0.0 6.5 ± 1.4 99.8 ± 0.2 — —
76.7 ± 0.0 50.3 ± 5.4 27.7 ± 0.0SOAP2 5.7 ± 1.6
100.0 ± 0.0 3.9 ± 0.8 99.9 ± 0.1 23.3 ± 2.2 100.0 ± 0.0
78.2 ± 0.0 99.8 ± 0.1 98.9 ± 0.0PBLAT 61.2 ± 6.8
100.0 ± 0.0 16.7 ± 1.3 99.6 ± 0.2 306.3 ± 23.3 52.7 ± 0.0
A.4.2 Impacts of Read Length
We evaluated the effect of varying the length of each read used during alignment to further
maximize the sensitivity, specificity, and minimize run time. Temporary read splitting and
trimming allows clinical samples from any sequencing technology to be analyzed without
compromising the speed and accuracy of the short read aligner or losing the alignment
specificity of longer reads. For the five simulated samples, varying read length had a larger
impact on runtime and sensitivity than adjusting internal parameters. Using Bowtie2 as
our primary aligner, 10 million 50 base reads were aligned against the human library in an
average 28 minutes, while aligning 100 base reads took on average 40 minutes. Depending
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on the reference library used, increasing read length may or may not increase sensitivity.
Bowtie2 aligned 50 base reads to the human library with an average sensitivity of 90% and
100 base reads with a decreased average sensitivity of 75%. This trend can be explained by
the splice junctions found in human transcriptome sequences. With fewer bases, the odds
of a read spanning a splice junction are smaller and the read will be more likely to align.
Conversely, when aligning reads against the bacterial and viral libraries, the average sensi-
tivity is 10-20% higher using 100 base reads compared to 50 base reads (see Additional file
6 online for complete results). To evaluate if longer reads continue to increase sensitivity, a
subset of 150 base simulated bacterial reads were tested. Results indicate that splitting the
150 base reads into 100 base and 50 base segments increased sensitivity by approximately
4 percent compared to leaving the reads at the full length of 150 bases. Thus, upon initi-
ation, Clinical PathoScope splits all long reads into fragments with a maximum length of
100 bases.
A.4.3 Library Alignment and Filtering Order
Various filtration methods were evaluated in an effort to minimize computation burden and
maximize accuracy. Five subtraction frameworks were evaluated: A) Naïve Approach,
B) Target Centric, C) Target Centric + Reassignment, D) Host Centric + Reassignment,
and E) Host Centric (Figure A.3). In the target centric approaches, reads are first aligned
against the target library followed by the host and non-target libraries. Conversely, in the
host centric approaches, reads are first aligned against the host and non-target libraries and
then against the target library. The naïve approach, or only aligning to the target library,
took the least amount of time, but resulted in the highest number of false positives. While
both the target centric and host centric filtration approaches yielded similar results in terms
of accuracy, the target centric approaches required ten fewer minutes to run to completion
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than the host centric approaches. The target centric approaches were more efficient because
a greater number of sequences were removed by initially mapping reads to the target library
than to the host library, thus reducing computational burden for subsequent alignments. To
determine the impact of the read reassignment algorithm, we compared the sensitivity of
both target centric approaches by analyzing our second set of simulated samples. With
viral pathogens as the target library, the target centric approach with read reassignment
achieved an average sensitivity of 97.8% for species and strain level identifications. With-
out the reassignment algorithm, the target centric approach achieved an average sensitivity
of 90.3% and 78.1% at the species and strain level, respectively. Concurrently, with bac-
terial pathogens as the target library, the target centric method with reassignment achieved
an average sensitivity of 77.6% and 72.8% at the species and strain levels, respectively,
compared with 52.8% and 41.7% for species and strain specific identifications without
read reassignment. These dramatic improvements in sensitivity between methods with and
without read reassignment demonstrate the necessity of this algorithm within the Clinical
PathoScope pipeline. The performance difference between viral and bacterial identification
can be directly attributed to the mixture of bacterial pathogens present in these simulated
samples. When two very closely related strains of the same species are present in a given
sample, Clinical PathoScope will tend to reassign reads which aligned to both strains to
the strain with more uniquely identifying sequences. Details regarding identification ac-
curacy of Clinical PathoScope with respect to each individual strain can be found online
(Additional file 3).
A.4.4 Optimal Clinical PathoScope Pipeline
The optimized Clinical PathoScope pipeline uses three reference genome libraries, four
alignments modules and the original PathoScope read reassignment algorithm to identify
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pathogens in a given sample (Figure A.4). First, all reads from a sample are mapped against
the reference genomes of the organisms of interest (target library, e.g. viruses) using up to
the first 100 bases of each read. This initial alignment results in the removal of the greatest
number of sequences by eliminating reads without strong sequence similarity to the target
genomes. Second, reads that aligned to the target library are aligned against the reference
library of the host species (host library) using the first 50 bases of each read. This step
allows for any residual host contamination to be identified and removed from the set of
candidate reads originating from the target genomes. Third, reads which did not align to
the host library are aligned against additional reference genomes (non-target library) known
to be negative targets of the analysis and which may overlap with the candidate read set.
Similar to step one, reads are aligned using the first 100 bases of each read to maintain high
specificity. Reads which did not align to the non-target library are realigned to the target
library allowing up to k alignments (e.g., we recommend k=10 for viral detection) per read
and subsequently passed to the read reassignment module in which reads with ambiguous
alignments are reassigned to their putative correct genome of origin. In summary, any se-
quencing read contributing to the identification of a pathogenic genome must 1) align to the
target genome library, 2) remain unaligned to the host genome library, 3) remain unaligned
to the non-target library, and 4) retain its to the target library. Finally, the pipeline pro-
duces a report detailing the number and proportion of reads originating from each genome
identified in a given sample.
A.4.5 Software Implementation and Distribution
The Clinical PathoScope pipeline has been implemented in open-source Python, and is
freely available for download at: http://sourceforge.net/projects/pathoscope/. The software
requires the user to supply a fastq read file (after conducting quality control), any number
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Figure A.4: Clinical PathoScope pipeline. A computational subtraction method using
varying sequence read lengths and ambiguous read reassignment. Unassembled sequencing
reads are aligned against a target library containing reference sequences of the intended
target(s) of identification (e.g. viruses). Reads aligned to the target library are then aligned
to a host library. Any reads aligned to the host sequences are removed from further analysis.
Next, reads are aligned against a library of known non-target sequences. Unaligned reads
are then mapped back to the target library, allowing up to k alignments per read (e.g. k=10).
These alignments are subsequently passed to an expectation maximization algorithm in
which ambiguous alignments are reassigned to their most probable genome of origin. Upon
reassignment, a report detailing the pathogens identified and their relative abundances is
produced.
of target, host, and non-target library Bowtie2 indices. Furthermore, the user has the op-
tion of changing the pipeline alignment parameters using inputs in the configuration file.
For convenience, our viral, bacterial, and human alignment indices are freely available for
download on the software distribution website. Clinical PathoScope will output two align-
ment files in SAM format, one directly from the Bowtie2 alignment, and another after read
reassignment. Finally, the pipeline will output a tab-delimited summary report containing
the genomes found in the sample as well as read numbers and proportions assigned to each
genome.
A.4.6 Evaluation of Clinical PathoScope on Clinical Data
Four clinical datasets were utilized to evaluate the efficacy of Clinical PathoScope across
a variety of scenarios (see Additional file 8 online for summary of datasets). In addition,
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Clinical PathoScope was evaluated side by side with two previously published pathogen
identification methods, RINS and READSCAN, on the basis of computational speed and
accuracy at identifying pathogens in clinical sequencing samples.
A.4.6.1 Prostate Cancer Cell Line (PCCL)
Clinical PathoScope was able to rapidly decode the viral composition of this dataset; identi-
fying the Human papillomavirus type 18 in fewer than 10 minutes. RINS and READSCAN
both produced similar results; however, they required approximately four times the com-
putational time to identify the pathogen, with run times of 89 minutes and 53 minutes,
respectively (Table A.2).
Table A.2: Run time comparisons of Clinical PathoScope and existing technologies
Average Run Time (minues)
Dataset Target Clinical PathoScope RINS READSCAN
Simulation Virus 4.5 84.1 193.6
Simulation Bacteria 13.1 1108.2 193.58
PCCL Virus 6.0 89.1 52.8
TMAdv Virus 4.4 144.0 78.6
Mummy Bacteria 25.0 1099.0 882.0
A.4.6.2 New World Titi Monkey Adenovirus Outbreak (TMAdv)
We examined Clinical PathoScope's performance in two clinical scenarios using the TMAdv
dataset. First, to evaluate our pipeline in cases where the exact strain is missing from the tar-
get library, we excluded the TMAdv strain from the target library. In this scenario, Clinical
PathoScope assigned reads to several adenovirus species (Figure A.5, Part A). According
to Chen et al., the Simian adenovirus 3, which was the top ranked virus in the Clinical
PathoScope result, is the closest phylogenetic relative to the TMAdv, with approximately
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56% sequence similarity. Despite its highly divergent nature, Clinical PathoScope was
able to successfully identify the closest phylogenetic neighbor of this novel species. Next,
as a positive control, we included the TMAdv genome in our target library and validated
that Clinical PathoScope accurately distinguished the TMAdv from all other adenovirus
genomes (Figure A.5, Part B), identifying 12,568 reads from TMAdv. In their original
analysis, Chen et al. used BLASTn [4] to identify 16,524 reads from TMAdv. This dis-
crepancy can be explained by the fact that BLASTn is a much more sensitive algorithm than
Bowtie2. This moderate increase in sensitivity, however, results in a dramatic increase in
run time, with BLASTn requiring ten times longer to complete the alignment than Bowtie2
when TMAdv is the only sequence in the database. Therefore, with rapid pathogen detec-
tion as the goal, a Bowtie2-based approach clearly provides a reasonable trade-off between
speed and sensitivity, whereas if genome assembly is the goal, a BLAST-based approach
might be preferable (at the cost of computational efficiency). Despite aligning approxi-
mately 4,000 fewer reads than the analysis in the original publication, we were still able
to obtain 22.0x coverage of the TMAdv genome. While it is clear that Clinical Patho-
Scope aligned substantially more reads with the TMAdv genome in the target library than
in its absence, we were still capable of generating a list of candidate relatives with read
counts proportional to their sequence similarity with the TMAdv. Furthermore, Clinical
PathoScope completed analysis of this dataset in less than 5 minutes (Table 2).
With the TMAdv genome in the reference library, both RINS and READSCAN were
able to accurately identify the correct viral genome in the sample. When the TMAdv
was removed from the library, RINS generated a single contiguous sequence consisting of
only 156 reads which mapped to 6 different adenovirus genomes, none of which included
the nearest phylogenetic neighbor. This shows that, while assembly may be possible in
a given sample, the ambiguous mapping of a contig to multiple genomes provides little
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Figure A.5: Alignment variations with and without TMAdv in the target library. A)
Without the TMAdv present in the target library, Clinical PathoScope assigned reads to
several adenovirus genomes. The identified genomes are displayed according to the pro-
portion of total reads aligned to all adenovirus genomes. The pairwise nucleotide identi-
ties of several adenovirus subtypes to the TMAdv genome according to Chen et al. are
given in parentheses. The Simian adenovirus 3 had the most reads aligned of all adenoviral
genomes, which is consistent with its sequence similarity to the TMAdv. Additionally, the
Human adenovirus D aligned the most reads of all human adenoviruses, which is consistent
with the analysis of Chen et al. B) Inclusion of the Titi Monkey Adenovirus (TMAdv) in the
target library resulted in the assignment of 12,568 reads to the TMAdv reference genome.
information pertaining to the true subspecies of origin. Additionally, RINS required 144
minutes to complete its analysis of this dataset. READSCAN assembled several contigs
of varying lengths and read counts from 16-60 reads per contig. However, the adenovirus
strains identified and ranked by READSCAN based on their relative genome abundance
score [70] were inconsistent with phylogenetic relationships found by Clinical PathoScope
and the original study [19]. Finally, READSCAN required approximately 80 minutes to
analyze this dataset.
A.4.6.3 Tuberculosis in a Mummy
To demonstrate the performance of Clinical PathoScope with respect to bacterial pathogen
identification, we analyzed a sample isolated from a mummy infected with tuberculosis.
Using assembled contigs and comparative genomics, Chan et al. found evidence the de-
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ceased was infected with two Mycobacterium tuberculosis genotypes. Using patterns of
deletions and SNPs, they concluded that both strains most closely resemble strain 7199/99,
but also share similarities with strain H37Rv. When strain 7199/99 was included in the tar-
get database, Clinical PathoScope associates 32% of the reads with strain 7199/99 and 25%
of reads with H37Rv. The majority of remaining reads were split between additional M.
tuberculosis strains and Nocardia species. Chan et al. also identified Nocardia species us-
ing their assembly approach. Clinical PathoScope successfully identified the most closely
related strains and furthermore, only required 25 minutes to complete the analysis. While
these results are in agreement with the author's nearest-neighbor findings, we note that the
number of M. tuberculosis strains in the sample (two unique strains according to Chan et
al.) cannot be inferred from the Clinical PathoScope output alone. To successfully con-
clude the presence of two unique strains in the sample, a more complex, assembly based
approach is required. Neither RINS nor READSCAN performed well on this dataset, re-
quiring 1099.0 and 882.25 minutes, respectively, to complete the analysis, likely due to the
large average read size of 297 bases and the complexity of the bacterial database. RINS as-
sembled 20,483 unique contigs of varying length and reported 1,044,193 unique alignments
of these contigs to 2,293 bacterial genomes. While vast, these results are uninformative as
to the specific strains present within the clinical sample. Several contigs were assigned to
various M. tuberculosis strains in the RINS report, however there was a tremendous lack
of specificity with regard to the specific strains present in the sample. With thousands of
other bacterial genomes identified and no metric for quantifying sequence abundance, the
user is forced to interpret the results of thousands of contigs and millions of potential align-
ments, many of which are redundant or uninformative. READSCAN required less time to
complete its analysis of the mummy dataset than RINS; however it also failed to generate
a report detailing any of the identified pathogens. In their original publication, the authors
102
demonstrate READSCAN primarily in the context of viral pathogen identification and note
its performance improvements over previous methods. As can be observed from its run
time on the mummy dataset, however, READSCAN has trouble scaling to larger bacterial
datasets with many closely related strains of the same species.
A.4.6.4 Bacterial Species Identificaiton from 16S Amplimer Sequences (16S)
Clinical PathoScope was also tested on eight 16S amplimer samples (Accession: SRP028704),
five originating from ATCC bacterial species, and three from patient tissue extracted from
intensive care patients with suspicion of bacterial infections. As shown in Table A.3, Clini-
cal PathoScope was able to successfully identify the unique bacterial species in each of the
first four ATCC samples with high accuracy. Furthermore, Clinical PathoScope was able
to accurately identify the correct mixture of ATCC species in the fifth sample, assigning
30.4%, 30.2%, 21.2%, and 15.9% of the reads to Escherichia coli, Enterococcus faecalis,
Pseudomonas aeruginosa, and Staphylococcus aureus, respectively.
For the three patient samples, we observed that the first sample (F1) contained a mixture
of Acinetobacter baumannii (57.6%) and Pseudomonas aeruginosa (40.4%), and that the
other two samples (G1 and H1) were dominated by Pseudomonas aeruginosa (94.6%) and
Enterobacter aerogenes (84.2%), respectively. To validate these results, we constructed
a phylogenetic tree of 16S genes from all genomes in the reference library that reside
within the three genera identified in the clinical samples (see Additional file 10 online).
We then visually inspected the read coverage pileup plots of 16S genes which are unique
between the species we identified and their phylogenetic neighbors (see Additional file 11
online). We observed that read coverage is uniform across the genomes identified by Clin-
ical PathoScope in each sample, resulting from the fact that they share 100% sequence
similarity of their 16S genes. In contrast, we noticed large coverage gaps in the nearest
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phylogenetic neighbors, indicating that there were sequence variants in these regions that
prohibited reads from aligning to these specific locations. This analysis further demon-
strates the highly specific and accurate framework employed by Clinical PathoScope and
its utility not only for strain-specific pathogen identifications, but also for 16S bacterial
classification.
A.4.7 Comparison to Metagenomic Pipelines
Clinical PathoScope has been designed to facilitate a rapid and streamlined approach to
identify strain-specific pathogens in noisy clinical sequencing samples. We compared our
method directly with two previously published algorithms, RINS and READSCAN, which
were designed specifically for pathogen identification in clinical samples. Additional meth-
ods, such as PathSeq [53] and IMSA [29], were also considered. These methods rely on
several BLAT and BLAST alignments in order to filter sequencing reads which can take
several hours to days to complete depending on the number of reads in a given sample.
To evaluate these types of approaches, we implemented a similar BLAST-based workflow
and applied this workflow to our second set of simulated samples with the bacterial library
as the target. This approach resulted in a substantial decrease in performance with only
48.3% and 34.8% sensitivity for species and strain-specific identifications, respectively.
This BLAST-based approach required 55 hours and 26 minutes, which is 300 times slower
than Clinical PathoScope. Therefore, these algorithms are not practical methods for rapid
clinical diagnostics.
We further expanded our comparisons to metagenomic pipelines that were not specif-
ically designed for the identification of pathogens in clinical samples but whose methods
or modules may be useful for the task. We first considered the CloVR-Metagenomics
pipeline which clusters raw sequencing reads to reduce redundancy followed by a simul-
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taneous BLASTX and BLASTN analysis against RefSeq and COG in order to annotate
each sequencing read. CLoVR-Metagenomics does not address the issue of host contami-
nation and thus wastes computational time clustering and annotating sequences originating
from the host which can account for >90% of the clinical sample. While very sensitive,
BLASTN is notoriously slow and does not scale well to large metagenomic samples [5],
making CLoVR-Metagenomics impractical for rapid strain identification. Furthermore, the
redundancy reduction procedures employed by CLoVR-Metagenomics collapse sequences
with 99% nucleotide similarity which could potentially remove reads which distinguish
two closely related strains of the same species.
We also considered assembly-based metAMOS [106] and phylogeny-based LMAT [5].
metAMOS offers a rich suite of assembly algorithms and pathogen annotation methods,
however it does not incorporate any methods to remove host or contaminating sequences.
As a result, the assembly of sequencing reads from a host-dominated clinical sample would
require an attempt to assemble the entire host genome. This will result in a substantial and
unnecessary increase in computational time and these contaminating reads could result in
high instances of false positive mappings. LMAT, a software package designed for tax-
onomy classification, does not report strain-level annotation of sequencing reads nor does
it report genome abundance information and thus cannot replicate the detailed pathogen
report produced by Clinical PathoScope.
A.5 Conclusions
Sequence-based diagnostic tools have the potential to revolutionize the treatment of pa-
tients in the clinic, particularly those suffering from viral and bacterial infections. As the
run times and error rates of modern sequencing technologies rapidly decline, it is essential
that software be developed to analyze these data in a manner that is both fast and highly
106
sensitive in order to provide physicians with the most accurate information possible. We
have implemented a novel pipeline for pathogen identification that overcomes many of the
challenges faced by current sequence-based methods including clinically appropriate run
time and subspecies specific assignment of sequencing reads. We have also demonstrated
our method's ability to identify multiple pathogens in a single clinical sample or the nearest
phylogenetic neighbor of highly mutated or divergent species. Furthermore, Clinical Patho-
Scope remained robust when analyzing datasets with lower than 1x coverage of the target
genomes. It should be noted, however, that as coverage drops below 1x, the probability
of sequencing a strain-specific segment of the target genome decreases. If these uniquely
identifying reads are not sequenced and thus not present in the sample, Clinical PathoScope
will tend to report the strain with the most aligned reads. Given that strain-specific reads
do exist within a given sample, we expect the lower limit of coverage required to make a
strain-specific identification to be comparable to our previously published results [34] in
which we demonstrated the efficacy of our read reassignment algorithm with as low at 20%
coverage of the genome.
The reference genome libraries used in this analysis contain all sequenced and assem-
bled viral and bacterial genomes from NCBI's RefSeq database. By avoiding genome as-
sembly in lieu of more rapid computation, Clinical PathoScope is limited in that it can only
identify pathogens that are present in these reference libraries. While the libraries used in
this study characterize the majority of known pathogens, they do not contain draft genomes.
To broaden and extend the application of Clinical PathoScope in future studies, we allow
the user to exchange, modify, or extend these libraries as more data becomes available.
By comparison with existing methods, we have demonstrated that our method is the
fastest strain-level pathogen identification algorithm currently available in the literature.
As the number of sequenced pathogens grows, the breadth of the reference libraries used
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with Clinical PathoScope will increase, thus expanding the search space required to assign
sequencing reads to a specific genome of origin. While this increase in search space will
result in a linear increase in run time, we assert that our method will not lose its computa-
tional advantage over existing methods.
In addition to faster run times and more accurate results, Clinical PathoScope offers a
user-friendly implementation. With only two dependencies, Bowtie2 and the PathoScope
reassignment algorithm, Clinical PathoScope can easily be installed and run on a stan-
dard desktop computer, facilitating a simplified workflow for the accurate identification
of pathogens in clinical sequencing samples. While designed for use by computational
biologists and biologists, the reports produced by Clinical PathoScope may prove useful
to physicians as they provide a complete picture of the microbial community of a given
clinical sample which may influence clinical diagnoses and treatment options.
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Appendix B
LUNG CANCER-ASSOCIATED GENES IN NASAL EPITHELIUM
Table B.1: 535 cancer-associated differentially expressed genes in nasal epithelium
Probeset Gene Symbol Direction Probeset Gene Symbol Direction
7892618 NA down 7912496 MTHFR down
7892678 NA down 7912537 NA down
7892766 NA down 7912638* TMEM51-AS1 down
7892947 NA down 7913256 DDOST down
7893061* NA down 7915184* NA down
7893173 NA down 7915543* SLC6A9 down
7893248 NA down 7915659 HECTD3 down
7893296* NA down 7918394* EPS8L3 down
7893333 NA down 7919872* FAM63A down
7893647 NA down 7920271* S100A4 down
7893862 NA down 7920291 NA down
7894331 NA down 7920642 MUC1 down
7894501 NA down 7923662* PIK3C2B down
7894737 NA down 7924150* TMEM206 down
7894926 NA down 7924823 JMJD4 down
7895180 NA down 7925876 NA down
7895602* NA down 7929882 SEMA4G down
7895618 NA down 7930537* TCF7L2 down
7896201 NA down 7931899 NA down
7896651 NA down 7934196* PSAP down
7901110* AKR1A1 down 7934477* CAMK2G down
7904830 RNF115 down 7935058 MYOF down
7905938 SLC50A1 down 7935188 NA down
7906079* RAB25 down 7937518 TSPAN4 down
7908147 TSEN15 down 7937713 SYT8 down
7910416 URB2 down 7938519* MICALCL down
7912412 MTOR down 7939546* CD82 down
7914563 YARS down 7939665* MDK down
7914834* PSMB2 down 7939767* MADD down
7915504 ELOVL1 down 7940160 DTX4 down
7915578* TMEM53 down 7940530 MYRF down
7917359 ZNHIT6 down 7940798 MARK2 down
7920971* C1orf85 down 7941621 DPP3 down
(continued on next page)
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(continued)
Probeset Gene Symbol Direction Probeset Gene Symbol Direction
7923483* RABIF down 7942697 NA down
7923929* PIGR down 7944164 TMPRSS4 down
7928630 EIF5AL1 down 7945204 ST14 down
7930031 GBF1 down 7945666 CTSD down
7930498* ACSL5 down 7946781* PLEKHA7 down
7930533 LOC143188 down 7947815* ACP2 down
7930577 CASP7 down 7948444 TCN1 down
7931778 PITRM1 down 7948588 SYT7 down
7933760* CCDC6 down 7949765 PPP1CA down
7934133 PPA1 down 7951309 MMP13 down
7934653 POLR3A down 7951896 PCSK7 down
7934753 NA down 7952132* SLC37A4 down
7936284* XPNPEP1 down 7952290 TRIM29 down
7937217* ECHS1 down 7953341* TAPBPL down
7938834 NAV2 down 7953483 USP5 down
7940775 RARRES3 down 7955613* KRT7 down
7944803* VWA5A down 7958989* PLBD2 down
7950248* FCHSD2 down 7962842 NA down
7950906* CTSC down 7964203* BAZ2A down
7951565* ARHGAP20 down 7969414 KLF5 down
7952557 SRPR down 7976000 ADCK1 down
7953395 COPS7A down 7976567 BDKRB1 down
7953981* ETV6 down 7977046* TNFAIP2 down
7958828 TRAFD1 down 7977249 INF2 down
7959153 COX6A1 down 7977511 TEP1 down
7962869 DDX23 down 7978260 DHRS1 down
7963187 LIMA1 down 7983405* DUOXA2 down
7967175 KDM2B down 7983478* C15orf48 down
7969794 LOC100132099 down 7983512* SQRDL down
7973314* OXA1L down 7984779 PML down
7973564* PSME1 down 7985240 TMED3 down
7979743 RDH11 down 7985620* ALPK3 down
7979757* ZFYVE26 down 7987230* LPCAT4 down
7980146* NPC2 down 7988350* DUOX2 down
7981824 NA down 7990417 SCAMP2 down
7985959* GDPGP1 down 7994737* NA down
7987536* RMDN3 down 7997152* CHST4 down
7988124 PPIP5K1 down 7997158 NA down
7988132* STRC down 7997401 BCO1 down
7989619 PPIB down 7998222* MRPL28 down
(continued on next page)
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(continued)
Probeset Gene Symbol Direction Probeset Gene Symbol Direction
7991323* PEX11A down 7999909* GPRC5B down
7993223* CLEC16A down 8000375* ARHGAP17 down
7996725 DUS2 down 8000543* NA down
7996908 SNTB2 down 8000811* MAPK3 down
7999791 NA down 8001030* PYCARD down
8002919 KARS down 8001552* CIAPIN1 down
8005994 ERAL1 down 8002133* PSMB10 down
8006392 PSMD11 down 8002421* VAC14 down
8006531 SLFN5 down 8005475 TRIM16L down
8006812* PSMB3 down 8005661* NA down
8007302* TUBG1 down 8006984 PSMD3 down
8007312* TUBG2 down 8007188 CNP down
8007715 NMT1 down 8007505* DHX8 down
8008139* UBE2Z down 8007620* GRN down
8009164* DCAF7 down 8008664 AKAP1 down
8010924 VPS53 down 8009666 RAB37 down
8011599 ANKFY1 down 8009693* TMEM104 down
8012856* ELAC2 down 8010354 GAA down
8013588 POLDIP2 down 8011293 CLUH down
8013641* PIGS down 8011516 ATP2A3 down
8014115 MYO1D down 8011671* GGT6 down
8014903* NA down 8011713* CXCL16 down
8015545 RAB5C down 8012126 CLDN7 down
8016099* EFTUD2 down 8014768 NA down
8021727 CNDP2 down 8017867* FAM20A down
8026106 CALR down 8018324* GGA3 down
8027876 TMEM147 down 8019211 NPLOC4 down
8028705 TIMM50 down 8019622 TMEM106A down
8028756 PSMC4 down 8021301 RAB27B down
8031827 ZNF587 down 8023043* PSTPIP2 down
8033912 DNMT1 down 8024687* TJP3 down
8036010* PEPD down 8028524 ACTN4 down
8042576* NAGK down 8029086 CEACAM5 down
8043100 TMSB10 down 8029098 CEACAM6 down
8043197 VAMP8 down 8029560 CLPTM1 down
8043937* CNOT11 down 8032789* STAP2 down
8047403* CASP10 down 8034420* MAN2B1 down
8048926 SP140L down 8034589* FARSA down
8058914 AAMP down 8037205 NA down
8059350 AP1S3 down 8037222 CEACAM8 down
(continued on next page)
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Probeset Gene Symbol Direction Probeset Gene Symbol Direction
8059361* WDFY1 down 8037794* PRKD2 down
8062349 RPN2 down 8038261* GYS1 down
8062981 PIGT down 8039389 PTPRH down
8063211 NCOA3 down 8040365* TRIB2 down
8063369* RNF114 down 8040698 SLC35F6 down
8064522* IDH3B down 8040753 TMEM214 down
8065832* TRPC4AP down 8043657* CNNM4 down
8066939* B4GALT5 down 8045539* NA down
8075585 RTCB down 8047738 NA down
8080938 MITF down 8048717 SGPP2 down
8086028 GLB1 down 8050160 MBOAT2 down
8088247 ARHGEF3 down 8051298* GALNT14 down
8088634 NA down 8051322 XDH down
8089544 CCDC80 down 8053214 AUP1 down
8089568 CD200R1 down 8053406 RETSAT down
8091385 CP down 8054054* NA down
8091991 NA down 8058390* RAPH1 down
8092169* TNFSF10 down 8058973 ZNF142 down
8092230 ZMAT3 down 8059222 DNPEP down
8092541 LIPH down 8060353* RBCK1 down
8093398* PCGF3 down 8062041* ACSS2 down
8093685 HTT down 8062251 NA down
8095139* SRD5A3 down 8062927* PI3 down
8098547 NA down 8063000* NA down
8102311* CASP6 down 8063078* CTSA down
8103911 IRF2 down 8063351* SLC9A8 down
8105077 CARD6 down 8063893 ADRM1 down
8108558* SLC35A4 down 8064613 SLC4A11 down
8108593* WDR55 down 8065612* NOL4L down
8114145 VDAC1 down 8065920* NA down
8116096 DDX41 down 8065948* FER1L4 down
8117243* LRRC16A down 8066513 SDC4 down
8117321* TRIM38 down 8068254* IL10RB down
8122013 L3MBTL3 down 8068810 SLC37A1 down
8122803* NA down 8069399* NA down
8123062 TMEM181 down 8070538 C2CD2 down
8123800* NA down 8072108 ASPHD2 down
8123951* ADTRP down 8072926* H1F0 down
8126588* XPO5 down 8073605* BIK down
8126729 NA down 8076569 TTLL12 down
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Probeset Gene Symbol Direction Probeset Gene Symbol Direction
8129254* MAN1A1 down 8076998* PLXNB2 down
8131631* HDAC9 down 8077082 LMF2 down
8133690* MDH2 down 8080100* RAD54L2 down
8134091* CLDN12 down 8082797 TF down
8135422* BCAP29 down 8084717* ST6GAL1 down
8136095 AHCYL2 down 8084895* MUC20 down
8136580 RAB19 down 8084929 SLC51A down
8139392 DDX56 down 8085300 SEC13 down
8147112* NA down 8087485 NA down
8148059 DEPTOR down 8088425* FAM3D down
8153474 TSTA3 down 8090823 SLCO2A1 down
8154733* ACO1 down 8092978 MUC4 down
8156770 GALNT12 down 8093230 NA down
8159249 MRPS2 down 8096070 BMP3 down
8160914 VCP down 8103025* ZNF827 down
8163452 FKBP15 down 8104079* FAT1 down
8165866 STS down 8106170 TMEM171 down
8168762 CSTF2 down 8114050* 8-Sep down
8169249 MID2 down 8115623* ATP10B down
8170882 ATP6AP1 down 8118833* UHRF1BP1 down
8173979* NOX1 down 8119926 TMEM63B down
8173999* XKRX down 8122843 ESR1 down
8175844 IDH3G down 8123606 SERPINB9P1 down
8179298* CSNK2B down 8125766 BAK1 down
8180343 RAC1 down 8129677* SGK1 down
7897728 FBXO6 down 8133721 HSPB1 down
7898799* C1QC down 8136849* GSTK1 down
7898805* C1QB down 8136863* TMEM139 down
7906355* CD1E down 8137798 PSMG3 down
7917561 GBP4 down 8139859* GUSB down
7919971* RFX5 down 8143575 EPHA1 down
7931951 SFMBT2 down 8144880* SH2D4A down
7934215* SPOCK2 down 8145027 FAM160B2 down
7938035* TRIM22 down 8145669* NA down
7942569* SLCO2B1 down 8146921 RDH10 down
7945962* TRIM21 down 8148548 PSCA down
7948274* UBE2L6 down 8148572* LY6E down
7949340 BATF2 down 8149330* CTSB down
7953428 CD4 down 8150036 KIF13B down
7953993 BCL2L14 down 8150112 GSR down
(continued on next page)
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(continued)
Probeset Gene Symbol Direction Probeset Gene Symbol Direction
7960947 A2M down 8152828 GSDMC down
7964119 STAT2 down 8153334 PSCA down
7978123* PSME2 down 8153342* LYPD2 down
7980958* LGMN down 8155707 NA down
7981290 WARS down 8156058 NA down
7993195* NA down 8157362* ZNF618 down
7995926* NLRC5 down 8157381* ZNF618 down
8006214* ADAP2 down 8158167* LCN2 down
8010426 RNF213 down 8158242* URM1 down
8010454 RNF213 down 8158671* NA down
8026971* IFI30 down 8158684* NA down
8029536* APOC1 down 8158961* GTF3C5 down
8034304* ACP5 down 8160670 AQP3 down
8057744 STAT1 down 8161174 GNE down
8066214 TGM2 down 8162502* FBP1 down
8066905 ZNFX1 down 8162729* TRIM14 down
8072710 APOL6 down 8162744* CORO2A down
8072735 APOL1 down 8163505* HDHD3 down
8075720 APOL2 down 8164535* CRAT down
8082075 DTX3L down 8164580* PTGES down
8086125* TRANK1 down 8172280* SLC9A7 down
8090018 PARP9 down 8175924* NAA10 down
8115147* CD74 down 8178115* CFB down
8117435* BTN3A2 down 8178561 ABHD16A down
8117458 BTN3A1 down 8179028 LOC554223 down
8117476* BTN3A3 down 8179112* ABCF1 down
8117760* HLA-F down 8179331* C2 down
8117777* NA down 8179351* CFB down
8118556* NA down 8179364* SKIV2L down
8118594* HLA-DPB1 down 8179638 TRIM26 down
8125463* NA down 8180166* TAPBP down
8125483 TAP2 down 7892796 NA up
8125993 ETV7 down 7893130 NA up
8140971 SAMD9L down 7894970* NA up
8143327 PARP12 down 7895574 NA up
8145317* ADAMDEC1 down 7896160 NA up
8146092* IDO1 down 7899502* RNU11 up
8161964 FRMD3 down 7902043* DNAJC6 up
8177732* HLA-A down 7916506* C1orf168 up
8178193* HLA-DRA down 7930612 NA up
(continued on next page)
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(continued)
Probeset Gene Symbol Direction Probeset Gene Symbol Direction
8178205* HLA-DQA2 down 7932498* SKIDA1 up
8179019* HLA-F down 7944765 NA up
8179041* NA down 7953383* SCARNA10 up
8179049* HLA-J down 7961710* ABCC9 up
8179481* HLA-DRA down 7964631 FAM19A2 up
8179489* NA down 7971165 NA up
8179495* PSMB9 down 7978407* PRKD1 up
8179519* HLA-DPB1 down 7985317* CEMIP up
8179731* NA down 7999291 C16orf89 up
8180003* NA down 8006504* FNDC8 up
8180022* NA down 8009380 SNORA38B up
8180029* HLA-DQB2 down 8013521* NA up
8180034* TAP2 down 8013523 NA up
8180049* PSMB8 down 8043782* CNGA3 up
8180061* TAP1 down 8045287* NA up
8180078* HLA-DMB down 8049530 LRRFIP1 up
8180086* HLA-DMA down 8076223* NA up
8180093* HLA-DOA down 8089145 ABI3BP up
8180100* HLA-DPA1 down 8098604 ANKRD37 up
7894264 NA down 8101762* SNCA up
7895149 NA down 8104141* PLEKHG4B up
7896038 NA down 8107204* NA up
7896908 PUSL1 down 8108180* NA up
7897263* RNF207 down 8127658 NA up
7898115* TMEM51 down 8132248 NA up
7898161* EFHD2 down 8147990 NA up
7903827 STRIP1 down 8156358 NA up
7904050* MOV10 down 8165694* NA up
7905881* ADAM15 down 8165696 NA up
7908694 NAV1 down 8165698* NA up
7908793 NA down 8165700 NA up
7909127 MFSD4 down 8165707 NA up
7909188* IKBKE down 8168868 ARMCX1 up
7912239 GPR157 down 8175531* CDR1 up
7912374 SRM down — — —
*indicates leading edge gene
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Appendix C
FUNCTIONAL ENRICHMENT (GENE ONTOLOGIES) OF
DOWN-REGULATED CANCER-ASSOCIATED GENES IN NASAL
EPITHELIUM
Table C.1: Significantly enriched GO terms among 492 down-regulated genes in patients
with lung cancer
Term FDR
antigen processing and presentation of exogenous antigen
(GO:0019884)
2.64E-13
antigen processing and presentation of exogenous peptide antigen
(GO:0002478)
2.64E-13
antigen processing and presentation of peptide antigen (GO:0048002) 8.84E-13
antigen processing and presentation (GO:0019882) 1.19E-11
antigen processing and presentation of exogenous peptide antigen via
MHC class I (GO:0042590)
1.74E-08
antigen processing and presentation of peptide antigen via MHC class
I (GO:0002474)
1.74E-08
antigen processing and presentation of exogenous peptide antigen via
MHC class I, TAP-dependent (GO:0002479)
6.31E-08
antigen processing and presentation of exogenous peptide antigen via
MHC class II (GO:0019886)
3.53E-05
antigen processing and presentation of peptide antigen via MHC class
II (GO:0002495)
3.53E-05
interferon-gamma-mediated signaling pathway (GO:0060333) 3.53E-05
antigen processing and presentation of peptide or polysaccharide anti-
gen via MHC class II (GO:0002504)
3.68E-05
signal transduction involved in mitotic G1 DNA damage checkpoint
(GO:0072431)
3.68E-05
intracellular signal transduction involved in G1 DNA damage check-
point (GO:1902400)
3.68E-05
DNA damage response, signal transduction by p53 class mediator re-
sulting in cell cycle arrest (GO:0006977)
3.68E-05
signal transduction involved in mitotic DNA integrity checkpoint
(GO:1902403)
3.68E-05
signal transduction involved in mitotic cell cycle checkpoint
(GO:0072413)
3.68E-05
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Term FDR
signal transduction involved in mitotic DNA damage checkpoint
(GO:1902402)
3.68E-05
signal transduction involved in DNA integrity checkpoint
(GO:0072401)
4.33E-05
signal transduction involved in DNA damage checkpoint
(GO:0072422)
4.33E-05
signal transduction involved in cell cycle checkpoint (GO:0072395) 4.71E-05
regulation of cellular amino acid metabolic process (GO:0006521) 7.97E-05
regulation of cellular amine metabolic process (GO:0033238) 0.000147804
positive regulation of cell cycle arrest (GO:0071158) 0.000198665
cellular response to interferon-gamma (GO:0071346) 0.000264094
DNA damage response, signal transduction by p53 class mediator
(GO:0030330)
0.000334076
response to interferon-gamma (GO:0034341) 0.000334076
negative regulation of G1/S transition of mitotic cell cycle
(GO:2000134)
0.000681069
negative regulation of cell cycle G1/S phase transition (GO:1902807) 0.000681069
negative regulation of ubiquitin-protein ligase activity involved in mi-
totic cell cycle (GO:0051436)
0.000741508
regulation of antigen processing and presentation (GO:0002577) 0.000976729
proteasome-mediated ubiquitin-dependent protein catabolic process
(GO:0043161)
0.000976729
regulation of cell cycle arrest (GO:0071156) 0.001026492
signal transduction in response to DNA damage (GO:0042770) 0.001086018
positive regulation of ubiquitin-protein ligase activity involved in mi-
totic cell cycle (GO:0051437)
0.001116512
proteasomal protein catabolic process (GO:0010498) 0.001272502
negative regulation of ligase activity (GO:0051352) 0.001272502
negative regulation of ubiquitin-protein transferase activity
(GO:0051444)
0.001272502
regulation of G1/S transition of mitotic cell cycle (GO:2000045) 0.001303525
regulation of cell cycle G1/S phase transition (GO:1902806) 0.001475051
signal transduction by p53 class mediator (GO:0072331) 0.001548279
regulation of ubiquitin-protein ligase activity involved in mitotic cell
cycle (GO:0051439)
0.00173373
regulation of cellular ketone metabolic process (GO:0010565) 0.001946114
antigen processing and presentation of endogenous antigen
(GO:0019883)
0.002234329
negative regulation of protein modification by small protein conjuga-
tion or removal (GO:1903321)
0.002330593
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Term FDR
anaphase-promoting complex-dependent proteasomal ubiquitin-
dependent protein catabolic process (GO:0031145)
0.002330593
post-translational protein modification (GO:0043687) 0.003201008
positive regulation of ubiquitin-protein transferase activity
(GO:0051443)
0.003523951
proteolysis involved in cellular protein catabolic process
(GO:0051603)
0.003541561
cytokine-mediated signaling pathway (GO:0019221) 0.004071611
protein catabolic process (GO:0030163) 0.004704633
positive regulation of ligase activity (GO:0051351) 0.004980771
regulation of antigen processing and presentation of peptide antigen
(GO:0002583)
0.005288359
negative regulation of protein ubiquitination (GO:0031397) 0.005404568
modification-dependent protein catabolic process (GO:0019941) 0.008295631
protein polyubiquitination (GO:0000209) 0.008295631
modification-dependent macromolecule catabolic process
(GO:0043632)
0.009325558
antigen processing and presentation of endogenous peptide antigen
via MHC class I (GO:0019885)
0.009413569
regulation of ubiquitin-protein transferase activity (GO:0051438) 0.010265072
antigen processing and presentation of endogenous peptide antigen
(GO:0002483)
0.012182104
negative regulation of protein modification process (GO:0031400) 0.012670399
regulation of ligase activity (GO:0051340) 0.013876213
ubiquitin-dependent protein catabolic process (GO:0006511) 0.013915779
regulation of apoptotic signaling pathway (GO:2001233) 0.014172597
positive regulation of antigen processing and presentation
(GO:0002579)
0.018895095
negative regulation of transferase activity (GO:0051348) 0.019241154
regulation of T cell activation (GO:0050863) 0.019692533
O-glycan processing (GO:0016266) 0.019692533
T cell costimulation (GO:0031295) 0.022242877
protein N-linked glycosylation via asparagine (GO:0018279) 0.022242877
regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043122) 0.022924012
lymphocyte costimulation (GO:0031294) 0.022924012
peptidyl-asparagine modification (GO:0018196) 0.022924012
positive regulation of T cell activation (GO:0050870) 0.023552255
T cell receptor signaling pathway (GO:0050852) 0.025340097
negative regulation of viral release from host cell (GO:1902187) 0.025340097
tRNA metabolic process (GO:0006399) 0.028902105
(continued on next page)
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(continued)
Term FDR
protein N-linked glycosylation (GO:0006487) 0.033855
regulation of cytokine production (GO:0001817) 0.03675597
G1/S transition of mitotic cell cycle (GO:0000082) 0.037323339
cell cycle G1/S phase transition (GO:0044843) 0.037323339
regulation of type I interferon production (GO:0032479) 0.04117111
positive regulation of protein modification by small protein conjuga-
tion or removal (GO:1903322)
0.048722949
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Appendix D
FUNCTIONAL ENRICHMENT (REACTOME PATHWAYS) OF
DOWN-REGULATED CANCER-ASSOCIATED GENES IN NASAL
EPITHELIUM
Table D.1: Significantly enriched Reactome pathways among 492 down-regulated genes in
patients with lung cancer
Pathway FDR
Pathway FDR
Interferon gamma signaling 9.67E-08
ER-Phagosome pathway 1.34E-07
Antigen processing-Cross presentation 1.74E-06
Interferon Signaling 3.74E-06
MHC class II antigen presentation 3.74E-06
Class I MHC mediated antigen processing and presentation 7.67E-05
Vpu mediated degradation of CD4 8.51E-05
AUF1 (hnRNP D0) destabilizes mRNA 0.000121945
Hh ligand biogenesis disease 0.000195641
Hedgehog ligand biogenesis 0.000195641
Processing-defective Hh variants abrogate ligand secretion 0.000195641
Ubiquitin-dependent degradation of Cyclin D1 0.000195641
Cross-presentation of soluble exogenous antigens (endosomes) 0.000195641
Autodegradation of the E3 ubiquitin ligase COP1 0.000195641
Regulation of activated PAK-2p34 by proteasome mediated degrada-
tion
0.000195641
Regulation of Apoptosis 0.000195641
CDK-mediated phosphorylation and removal of Cdc6 0.000195641
p53-Independent DNA Damage Response 0.000195641
Stabilization of p53 0.000195641
Ubiquitin-dependent degradation of Cyclin D 0.000195641
Regulation of ornithine decarboxylase (ODC) 0.000195641
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A 0.000195641
p53-Independent G1/S DNA damage checkpoint 0.000195641
Programmed Cell Death 0.000195641
Vif-mediated degradation of APOBEC3G 0.000217936
degradation of AXIN 0.000233466
(continued on next page)
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(continued)
Pathway FDR
SCF-beta-TrCP mediated degradation of Emi1 0.000233466
Apoptosis 0.000240853
degradation of DVL 0.000278897
SCF(Skp2)-mediated degradation of p27/p21 0.000278897
p53-Dependent G1 DNA Damage Response 0.000300021
p53-Dependent G1/S DNA damage checkpoint 0.000300021
CDT1 association with the CDC6:ORC:origin complex 0.000332971
Degradation of GLI2 by the proteasome 0.000339044
GLI3 is processed to GLI3R by the proteasome 0.000339044
Degradation of GLI1 by the proteasome 0.000339044
Antigen Presentation: Folding, assembly and peptide loading of class
I MHC
0.000339044
G1/S DNA Damage Checkpoints 0.000366337
Autodegradation of Cdh1 by Cdh1:APC/C 0.000366337
Asymmetric localization of PCP proteins 0.000520438
Cytokine Signaling in Immune system 0.000527352
AMER1 mutants destabilize the destruction complex 0.000527352
Host Interactions of HIV factors 0.000527352
Degradation of beta-catenin by the destruction complex 0.000527352
phosphorylation site mutants of CTNNB1 are not targeted to the pro-
teasome by the destruction complex
0.000527352
S33 mutants of beta-catenin arent phosphorylated 0.000527352
truncated APC mutants destabilize the destruction complex 0.000527352
deletions in the AXIN genes in hepatocellular carcinoma result in el-
evated WNT signaling
0.000527352
APC/C:Cdc20 mediated degradation of Securin 0.000527352
deletions in the AMER1 gene destabilize the destruction complex 0.000527352
Activation of NF-kappaB in B cells 0.000527352
T41 mutants of beta-catenin arent phosphorylated 0.000527352
Assembly of the pre-replicative complex 0.000527352
Cyclin E associated events during G1/S transition 0.000527352
Cyclin A:Cdk2-associated events at S phase entry 0.000527352
AXIN mutants destabilize the destruction complex, activating WNT
signaling
0.000527352
APC truncation mutants have impaired AXIN binding 0.000527352
misspliced GSK3beta mutants stabilize beta-catenin 0.000527352
truncations of AMER1 destabilize the destruction complex 0.000527352
APC truncation mutants are not K63 polyubiquitinated 0.000527352
TCF7L2 mutants dont bind CTBP 0.000527352
S45 mutants of beta-catenin arent phosphorylated 0.000527352
(continued on next page)
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(continued)
Pathway FDR
S37 mutants of beta-catenin arent phosphorylated 0.000527352
AXIN missense mutants destabilize the destruction complex 0.000527352
Cdc20:Phospho-APC/C mediated degradation of Cyclin A 0.000633046
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1
targeted proteins in late mitosis/early G1
0.000633046
Orc1 removal from chromatin 0.000675581
Switching of origins to a post-replicative state 0.000675581
APC:Cdc20 mediated degradation of cell cycle proteins prior to satis-
fation of the cell cycle checkpoint
0.000675581
Regulation of mRNA stability by proteins that bind AU-rich elements 0.000714235
Translocation of ZAP-70 to Immunological synapse 0.000775763
Removal of licensing factors from origins 0.000790727
APC/C:Cdc20 mediated degradation of mitotic proteins 0.000790727
Activation of APC/C and APC/C:Cdc20 mediated degradation of mi-
totic proteins
0.00086583
PCP/CE pathway 0.001044257
Regulation of DNA replication 0.001044257
Phosphorylation of CD3 and TCR zeta chains 0.001096031
Regulation of APC/C activators between G1/S and early anaphase 0.001227277
Antigen processing: Ubiquitination and Proteasome degradation 0.001659741
M/G1 Transition 0.001865994
DNA Replication Pre-Initiation 0.001865994
PD-1 signaling 0.001865994
Regulation of mitotic cell cycle 0.001992622
APC/C-mediated degradation of cell cycle proteins 0.001992622
Hedgehog on state 0.002347439
beta-catenin independent WNT signaling 0.00307868
Post-translational protein modification 0.004508296
Synthesis of DNA 0.00577858
Hedgehog off state 0.00577858
Defective ALG14 causes congenital myasthenic syndrome (ALG14-
CMS)
0.00577858
Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2 0.00577858
Defective ALG1 causes ALG1-CDG (CDG-1k) 0.00577858
Diseases associated with N-glycosylation of proteins 0.00577858
Defective MGAT2 causes MGAT2-CDG (CDG-2a) 0.00577858
Asparagine N-linked glycosylation 0.00577858
Defective ALG8 causes ALG8-CDG (CDG-1h) 0.00577858
Defective ALG3 causes ALG3-CDG (CDG-1d) 0.00577858
Defective MAN1B1 causes MRT15 0.00577858
(continued on next page)
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(continued)
Pathway FDR
Defective RFT1 causes RFT1-CDG (CDG-1n) 0.00577858
Defective MOGS causes MOGS-CDG (CDG-2b) 0.00577858
Defective ALG12 causes ALG12-CDG (CDG-1g) 0.00577858
Defective ALG11 causes ALG11-CDG (CDG-1p) 0.00577858
Defective MPDU1 causes MPDU1-CDG (CDG-1f) 0.00577858
Defective ALG6 causes ALG6-CDG (CDG-1c) 0.00577858
Defective ALG2 causes ALG2-CDG (CDG-1i) 0.00577858
Defective ALG9 causes ALG9-CDG (CDG-1l) 0.00577858
Generation of second messenger molecules 0.00577858
Cytosolic tRNA aminoacylation 0.007162194
DNA Replication 0.008363424
Metabolism of amino acids and derivatives 0.009108996
Costimulation by the CD28 family 0.009480799
G1/S Transition 0.010558502
HIV Infection 0.012592713
Downstream TCR signaling 0.015279044
Signaling by Hedgehog 0.0155106
Cell Cycle Checkpoints 0.017533124
O-linked glycosylation of mucins 0.020634049
S Phase 0.024013619
Downstream signaling events of B Cell Receptor (BCR) 0.027494356
Mitotic G1-G1/S phases 0.041088537
Separation of Sister Chromatids 0.048272892
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Appendix E
FUNCTIONAL ENRICHMENT (GENE ONTOLOGIES) OF UP-REGULATED
CANCER-ASSOCIATED GENES IN NASAL EPITHELIUM
Table E.1: Significantly enriched GO terms among 43 up-regulated genes in patients with
lung cancer.
Term FDR
response to magnesium ion (GO:0032026) 0.011781464
positive regulation of release of sequestered calcium ion into cytosol
(GO:0051281)
0.011781464
potassium ion transport (GO:0006813) 0.011781464
cellular potassium ion transport (GO:0071804) 0.011781464
potassium ion transmembrane transport (GO:0071805) 0.011781464
regulation of endocytosis (GO:0030100) 0.01247912
positive regulation of calcium ion transport into cytosol
(GO:0010524)
0.019093938
regulation of release of sequestered calcium ion into cytosol
(GO:0051279)
0.035743385
regulation of vesicle-mediated transport (GO:0060627) 0.048085808
regulation of calcium ion transport into cytosol (GO:0010522) 0.048085808
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Appendix F
NASAL LUNG CANCER CLASSIFIER GENES
Table F.1: Nasal classifier genes
Probeset ID Gene Symbol Probeset ID Gene Symbol
8091385 CP 8117476 BTN3A3
8115147 CD74 8180078 HLA-DMB
8034420 MAN2B1 7925876 NA
8075720 APOL2 8092978 MUC4
7940775 RARRES3 7940160 DTX4
8125463 NA 8076998 PLXNB2
7912638 TMEM51-AS1 8179041 NA
7978123 PSME2 8145317 ADAMDEC1
7937217 ECHS1 8180049 PSMB8
8002133 PSMB10 7993195 NA
8084895 MUC20 7929882 SEMA4G
8180166 TAPBP 8179049 HLA-J
8179331 C2 7947815 ACP2
8146092 IDO1 8096070 BMP3
7898115 TMEM51 8063000 NA
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Appendix G
RABBIT PARALLEL PROCESSING SHELL SCRIPT
$ #!/bin/bash
$
$ cd /restricted/projectnb/pulmarray/rabbit/
$
$ mkdir logs
$
$ VAR=$RANDOM
$ NCV=10
$ PREFIX="stock_pipeline"
$
$ for i in ‘seq 1 $NCV‘
$ do
$ ID=$PREFIX"_fold_"$i
$ LOG="logs/"$ID".qlog"
$ qsub -N $ID -o $LOG scripts/run_stock_pipeline.qsub $i
$ done
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Appendix H
RABBIT PARALLEL PROCESSING QSUB SCRIPT
#!/bin/bash -l
#
# Run this file using ’qsub job.sh’
#
# All lines starting with "#$" are SGE qsub commands
#
# Specify which shell to use
#$ -S /bin/bash
# Run on the current working directory
#$ -cwd
# Join standard output and error to a single file
#$ -j y
# Send an email when the job begins and when it ends running
#$ -m be
# Whom to send the email to
#$ -M jperezr1@bu.edu
# Assign a project to this job
#$ -P pulmarray
echo "=========================================================="
echo "Starting on : $(date)"
echo "Running on node : $(hostname)"
echo "Current directory : $(pwd)"
echo "Current job ID : $JOB_ID"
echo "Current job name : $JOB_NAME"
echo "Task index number : $TASK_ID"
echo "=========================================================="
echo ""
module load R/R-3.1.1
127
R --no-save < /restricted/projectnb/pulmarray/rabbit/scripts/
+ run_stock_pipeline.R --args $1
echo ""
echo "=========================================================="
echo "$JOB_ID finished on : $(date)"
echo "=========================================================="
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